[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 535
1. Garcia JJ, Al-Ahmadie HA, Gopalan A, Tickoo SK, Scardino PT, Reuter VE, Fine SW: Do prostatic transition zone tumors have a distinct morphology? Am J Surg Pathol; 2008 Nov;32(11):1709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have proposed that the morphologic spectrum of prostatic glands of variable size with tall columnar cells displaying basally oriented nuclei and clear to pale pink cytoplasm (TZ-LOOK) is characteristic of the well to moderately differentiated component of transition zone (TZ) tumors.
  • Each dominant tumor was assigned a TZ-LOOK extent score of 0 to 4, with 0 = no such morphology, 1 = 1% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = >75%.
  • In tumors of both zones with predominant (scores 3 to 4; >50%) TZ-LOOK histology, darker glands of usual acinar adenocarcinoma was often seen at the periphery.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem Suppl. 1994;19:267-9 [7823599.001]
  • [Cites] Urology. 2003 Apr;61(4):748-53 [12670559.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] J Urol. 1995 Nov;154(5):1795-7 [7563349.001]
  • [Cites] J Urol. 1996 Feb;155(2):605-6 [8558670.001]
  • [Cites] Urology. 1996 Nov;48(5):751-6 [8911519.001]
  • [Cites] J Urol. 1997 Jan;157(1):204-6 [8976251.001]
  • [Cites] J Urol. 1997 Feb;157(2):556-8 [8996355.001]
  • [Cites] J Urol. 1997 Nov;158(5):1886-90 [9334623.001]
  • [Cites] Int J Urol. 1997 Nov;4(6):567-71 [9477185.001]
  • [Cites] Urology. 1998 Jul;52(1):89-93 [9671876.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1239-46 [9777986.001]
  • [Cites] Eur Urol. 1999 Apr;35(4):294-7 [10087391.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1221-5 [15610093.001]
  • [Cites] J Urol. 2005 Mar;173(3):737-41 [15711259.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1189-93 [14501722.001]
  • [Cites] Radiology. 2003 Oct;229(1):241-7 [12920178.001]
  • [Cites] Pathology. 2003 Dec;35(6):467-71 [14660095.001]
  • [Cites] Invest Urol. 1978 Jan;15(4):340-5 [75197.001]
  • [Cites] Prostate. 1981;2(1):35-49 [7279811.001]
  • [Cites] J Urol. 1988 Jan;139(1):61-5 [3336108.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):619-33 [2456702.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):897-906 [3202246.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] J Urol. 1991 Jul;146(1):78-83; discussion 83-4 [1711589.001]
  • [Cites] J Urol. 1991 Oct;146(4):1069-76 [1895423.001]
  • [Cites] Br J Urol. 1991 Nov;68(5):499-509 [1747726.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):258-66 [1555836.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] Cancer Invest. 1994;12(4):425-37 [8032966.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):863-70 [7520673.001]
  • [Cites] Urol Int. 2005;74(1):23-6 [15711104.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):916-21; discussion 921 [16126324.001]
  • [Cites] BJU Int. 2006 Dec;98(6):1167-71 [17026586.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):430-5 [17412489.001]
  • [Cites] Adv Anat Pathol. 2007 Nov;14(6):401-7 [18049129.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):229-35 [18223325.001]
  • [Cites] J Urol. 2008 Apr;179(4):1335-8; discussion 1338-9 [18289601.001]
  • [Cites] J Urol. 2000 Jun;163(6):1751-5 [10799175.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1039-46 [10935644.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):441-6 [11331962.001]
  • [Cites] BJU Int. 2002 Jan;89(1):33-9 [11849157.001]
  • [Cites] Urology. 2001 Jun;57(6):1117-20 [11377321.001]
  • [Cites] BJU Int. 2002 Jun;89(9):886-9 [12010233.001]
  • [Cites] Semin Surg Oncol. 1995 Jan-Feb;11(1):9-22 [7754280.001]
  • (PMID = 18769336.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092629-10; United States / NCI NIH HHS / CA / P50 CA092629; United States / NCI NIH HHS / CA / P50 CA092629-10
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS237591; NLM/ PMC3010973
  •  go-up   go-down


2. Martínez-Romero C, Rooman I, Skoudy A, Guerra C, Molero X, González A, Iglesias M, Lobato T, Bosch A, Barbacid M, Real FX, Hernández-Muñoz I: The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol; 2009 Oct;219(2):205-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC) are associated with major changes in cell differentiation.
  • We hypothesized that Polycomb might play a role in preneoplastic states in the pancreas and in tumour development/progression.
  • To obtain mechanistic insights, Bmi1 expression in cells undergoing in vitro exocrine cell metaplasia and the effects of Bmi1 depletion in an acinar cancer cell line were studied.
  • We found that Bmi1 and Ring1B are expressed in pancreatic exocrine precursor cells during early development and in ductal and islet cells-but not acinar cells-in the adult pancreas.
  • Bmi1 expression was induced in acinar cells during acute injury, in acinar-ductal metaplastic lesions, as well as in pancreatic intraepithelial neoplasia (PanIN) and PDAC.
  • Bmi1 knockdown in cultured acinar tumour cells led to changes in the expression of various digestive enzymes.
  • Our results suggest that Bmi1 and Ring1B are modulated in pancreatic diseases and could contribute differently to tumour development.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / metabolism. Pancreatitis, Chronic / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 19585519.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Bmi1 protein, mouse; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / transcription factor PTF1; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


3. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R: Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. Int J Immunopathol Pharmacol; 2009 Jul-Sep;22(3):755-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer.
  • High expression of prostate stem cell antigen (PSCA) has been shown to be associated with adverse prognostic features in clinically-diagnosed prostate cancer.
  • PSCA expression was evaluated immunohistochemically in normal-looking epithelium (NEp), high-grade prostatic intraepithelial neoplasia (HGPIN) and pT2a Gleason score 6 acinar adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Carcinoma, Acinar Cell / immunology. Immunohistochemistry. Incidental Findings. Membrane Glycoproteins / analysis. Neoplasm Proteins / analysis. Prostatic Intraepithelial Neoplasia / immunology. Prostatic Neoplasms / immunology. Urinary Bladder Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm. Cell Transformation, Neoplastic / immunology. GPI-Linked Proteins. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Prostatectomy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822092.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / GPI-Linked Proteins; 0 / Ki-67 Antigen; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human
  •  go-up   go-down


Advertisement
4. Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, Escourrou J, Buscail L, Cordelier P: let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther; 2009 Aug;20(8):831-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression.
  • Let-7 is present in normal acinar pancreatic cells, and lost in poorly differentiated cancer samples.
  • Restoring let-7 levels in cancer-derived cell lines strongly inhibits cell proliferation, K-ras expression, and mitogen-activated protein kinase activation, but fails to impede tumor growth progression after intratumoral gene transfer or after implantation of Capan-1 cells stably overexpressing let-7 microRNA.
  • [MeSH-major] MicroRNAs / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Animals. Biopsy, Fine-Needle. Cell Line, Tumor. Cell Proliferation. Disease Progression. Enzyme Activation. Female. Gene Expression Regulation, Neoplastic. Genes, ras. Humans. Male. Mice. Middle Aged. Mitogen-Activated Protein Kinases / metabolism. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323605.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / mirnlet7 microRNA, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


5. Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA: Molecular pathology of prostate cancer. Cancer Biomark; 2010;9(1-6):441-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In spite of the large number of tissue cores, the amount of tumor available for study is often quite limited.
  • With the exception of ductal variants, recognized subtypes of prostate cancer are largely confined to research applications, and most prostate cancers are acinar.
  • The chapter concludes with an overview of blood biomarkers such as circulating nucleic acids and tumor cells and bound/free isoforms of prostate specific antigen (PSA).
  • [MeSH-major] Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Early Detection of Cancer. Humans. Male. Proteomics


6. Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, Feldmann G, Stoffers DA, Konieczny SF, Leach SD, Maitra A: Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A; 2008 Dec 2;105(48):18913-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice.
  • Pancreatic ductal adenocarcinoma (PDAC) is believed to arise through a multistep model comprised of putative precursor lesions known as pancreatic intraepithelial neoplasia (PanIN).
  • Recent genetically engineered mouse models of PDAC demonstrate a comparable morphologic spectrum of murine PanIN (mPanIN) lesions.
  • The most faithful genetic models activate an oncogenic Kras(G12D) knockin allele within the pdx1- or ptf1a/p48-expression domain of the entire pancreatic anlage during development, thus obscuring the putative cell(s)-of-origin from which subsequent mPanIN lesions arise.
  • In our study, activation of this knockin Kras(G12D) allele in the Elastase- and Mist1-expressing mature acinar compartment of adult mice resulted in the spontaneous induction of mPanIN lesions of all histological grades, although invasive carcinomas per se were not seen.
  • We observed no requirement for concomitant chronic exocrine injury in the induction of mPanIN lesions from the mature acinar cell compartment.
  • The acinar cell derivation of the mPanINs was established through lineage tracing in reporter mice, and by microdissection of lesional tissue demonstrating Cre-mediated recombination events.
  • We conclude that in the appropriate genetic context, the differentiated acinar cell compartment in adult mice retains its susceptibility for spontaneous transformation into mPanIN lesions, a finding with potential relevance vis-à-vis the origins of PDAC.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6N.129S6-Bhlha15<tm2(Kras)Skz>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Nat Med. 2002 Sep;8(9):979-86 [12185362.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:71-89 [14570564.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:13 [12636873.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] J Surg Oncol. 1975;7(2):139-41 [1097831.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Nature. 1984 Nov 1-7;312(5989):71-5 [6092966.001]
  • [Cites] Yale J Biol Med. 1992 Sep-Oct;65(5):457-64; discussion 465-9 [1340063.001]
  • [Cites] Int J Pancreatol. 1999 Apr;25(2):77-87 [10360219.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S78-82 [15758664.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):728-41 [15765408.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] Cell Cycle. 2006 Jan;5(1):43-6 [16322695.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3161-73 [17114586.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):451-3 [17157783.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):211-3 [17349578.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4419-24 [17360539.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Cell. 2008 Jan 25;132(2):197-207 [18243096.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):621-31 [18515092.001]
  • (PMID = 19028870.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK56211; United States / NIDDK NIH HHS / DK / R21 DK072532-01; United States / NCI NIH HHS / CA / R01 CA113669-02; United States / NIDDK NIH HHS / DK / R21 DK072532-02; United States / NCI NIH HHS / CA / R01 CA113669-01; United States / NCI NIH HHS / CA / CA113669-02; United States / NCI NIH HHS / CA / CA113669-04; United States / NIDDK NIH HHS / DK / DK072532-01; United States / NCI NIH HHS / CA / CA113669-03; United States / NCI NIH HHS / CA / CA113669; United States / NIDDK NIH HHS / DK / DK55489; United States / NIDDK NIH HHS / DK / DK072532; United States / NIDDK NIH HHS / DK / R01 DK055489-11A1; United States / NIDDK NIH HHS / DK / R01 DK055489; United States / NCI NIH HHS / CA / R01 CA124586-04; United States / NCI NIH HHS / CA / R01 CA113669-05; United States / NIDDK NIH HHS / DK / DK61215; United States / NIDDK NIH HHS / DK / R21 DK072532; United States / NIDDK NIH HHS / DK / R01 DK061215; United States / NCI NIH HHS / CA / R01 CA113669-03; United States / NCI NIH HHS / CA / CA124586-04; United States / NIDDK NIH HHS / DK / T32 DK007713; United States / NCI NIH HHS / CA / R01 CA124586; United States / NIDDK NIH HHS / DK / T32DK007713; United States / NCI NIH HHS / CA / CA124586; United States / NIDDK NIH HHS / DK / DK055489-11A1; United States / NCI NIH HHS / CA / R01 CA113669; United States / NIDDK NIH HHS / DK / R01 DK056211; United States / NCI NIH HHS / CA / R01 CA113669-04; United States / NCI NIH HHS / CA / CA113669-05; United States / NIDDK NIH HHS / DK / DK072532-02; United States / NCI NIH HHS / CA / CA113669-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2596215
  •  go-up   go-down


7. Hasteh F, Pu R, Michael CW: A metastatic renal carcinoid tumor presenting as breast mass: a diagnostic dilemma. Diagn Cytopathol; 2007 May;35(5):306-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A metastatic renal carcinoid tumor presenting as breast mass: a diagnostic dilemma.
  • We present clinicopathological and cytological findings of a well-defined breast mass in a patient with history of primary renal carcinoid tumor.
  • Fine-needle aspiration (FNA) cytology showed monotonous tumor cells with plasmacytoid appearance arranged singly and in small clusters.
  • Occasional tumor cells were arranged in acinar architecture resembling glandular differentiation.
  • Tumor cells showed fine speckled chromatin.
  • The unusual location for metastasis of this rare type of carcinoid tumor and overlapping cytological features with primary mammary carcinoma led to an erroneous preliminary cytological diagnosis of primary breast carcinoma with plasmacytoid features.
  • Tumor cells in the corresponding cell block showed strong diffuse positivity for synapthophysin and pan-cytokeratin with weak focal positivity for chromogranin markers.
  • These patterns of immunostaining were similar to the original renal carcinoid tumor.
  • To the best of our knowledge, a few cases of carcinoid tumor metastatic to the breast have been reported in the literature and more than half of these cases were initially misdiagnosed as primary breast carcinoma causing unnecessary surgical treatment.
  • This is a first reported case of metastatic renal carcinoid tumor into breast diagnosed with FNA biopsy.
  • This report highlights the cytological features of well-differentiated neuroendocrine tumor (carcinoid tumor) and its potential diagnostic pitfalls.
  • [MeSH-major] Biopsy, Fine-Needle. Breast Neoplasms / secondary. Carcinoid Tumor / secondary. Kidney Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chromogranins / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Middle Aged. Synaptophysin / analysis

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427210.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranins; 0 / Synaptophysin; 68238-35-7 / Keratins
  •  go-up   go-down


8. Sorscher SM: Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report. Eur J Cancer Care (Engl); 2009 May;18(3):318-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
  • Acinar cell carcinoma of the pancreas is rare tumour with a generally poor prognosis.
  • There are very few reports of tumour regression following chemotherapy.
  • In this case report, a patient with metastatic acinar cell carcinoma in the liver developed progressive disease after cisplatin/etoposide and then had progressive disease after weekly paclitaxel chemotherapy.
  • However, his tumour then responded to gemcitibine/5-flourouracil/leucovorin chemotherapy.
  • Herein, previously described chemotherapy regimens used for this rare tumour are reviewed.
  • This case represents the first reported metastatic acinar cell carcinoma responding to this regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Treatment Outcome. Vitamin B Complex / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445023.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 12001-76-2 / Vitamin B Complex; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med; 2008 May;37(5):309-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were to determine the expression of Mcm-2, Ki-67 and geminin in salivary gland (SG) tumours, and to evaluate their usefulness for diagnosis or for prediction of tumour behaviour.
  • There were 13 adenoid cystic carcinomas (ACC), 10 carcinoma ex pleomorphic adenomas (CEPA), 10 mucoepidermoid carcinomas (MEC), 10 polymorphous low-grade adenocarcinomas (PLGA), 10 pleomorphic adenomas (PA) and nine acinic cell carcinomas (AcCC).
  • LI did not correlate to tumour grade or outcome for any of the markers or tumour types.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cell Cycle Proteins / biosynthesis. Ki-67 Antigen / biosynthesis. Nuclear Proteins / biosynthesis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Geminin. Humans. Immunoenzyme Techniques. Male. Microarray Analysis. Middle Aged. Minichromosome Maintenance Complex Component 2. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248354.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


10. Mueller SB, Micke O, Herbst H, Schaefer U, Willich N: Alpha-fetoprotein-positive carcinoma of the pancreas: a case report. Anticancer Res; 2005 May-Jun;25(3A):1671-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of a 19-year-old male with an alpha-fetoprotein (AFP)-producing acinar cell carcinoma of the pancreas.
  • Tumour markers other than AFP were normal.
  • Initially, the tumour showed a good response to irradiation and 5-fluorouracil (5-FU) application, and therapy showed sufficient local control.
  • The patient died 18 months after the initial therapy due to general tumour progression.
  • Originally, AFP was thought to be specific to hepatocellular carcinoma and germ cell tumours.
  • Rare cases of acinar cell carcinomas of the pancreas were found to express AFP.
  • [MeSH-major] Pancreatic Neoplasms / metabolism. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033080.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


11. Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J, Song L: Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer; 2010;10:495
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Phosphotransferases (Alcohol Group Acceptor) / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism
  • [MeSH-minor] Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Blotting, Western. Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cohort Studies. Disease Progression. Female. Gamma Rays. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucoepidermoid Tumor / genetics. Mucoepidermoid Tumor / metabolism. Mucoepidermoid Tumor / pathology. Palliative Care. Prognosis. RNA, Messenger / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Res. 2003 May;47(5):401-7 [12676514.001]
  • [Cites] Histopathology. 2003 Apr;42(4):348-56 [12653946.001]
  • [Cites] J Atheroscler Thromb. 2003;10(3):125-31 [14564080.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):914-8 [14645349.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1040-4 [15252310.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7359-69 [15314148.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] J Craniomaxillofac Surg. 1996 Jun;24(3):133-9 [8842902.001]
  • [Cites] Science. 1998 Mar 6;279(5356):1552-5 [9488656.001]
  • [Cites] Head Neck. 1999 Aug;21(5):414-9 [10402521.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3169-77 [15632208.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2526-33 [15900577.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Aug;64(8):695-705 [16106218.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1808-16 [15890687.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11667-75 [16357178.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 21;342(4):1284-90 [16516161.001]
  • [Cites] Leukemia. 2006 Jan;20(1):95-102 [16281067.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Aug;318(2):596-603 [16632640.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7211-23 [16980623.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1758(12):2016-26 [16996023.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Jun;264(6):587-94 [17415578.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3661-6 [17972532.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):54-8 [18091319.001]
  • [Cites] Leukemia. 2008 May;22(5):971-9 [18401414.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3319-26 [18519759.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1393-9 [19228740.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):545-58 [10545499.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):518-23 [10649241.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):836-9 [10835516.001]
  • [Cites] Curr Biol. 2000 Nov 30;10(23):1527-30 [11114522.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):385-402 [10880336.001]
  • [Cites] J Neurochem. 2001 Mar;76(5):1573-84 [11238741.001]
  • [Cites] Laryngorhinootologie. 2001 Sep;80(9):525-9 [11555785.001]
  • [Cites] Pathol Res Pract. 2001;197(9):621-6 [11569926.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):72-80 [12069812.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1784-5 [12176575.001]
  • [Cites] Exp Cell Res. 2002 Nov 15;281(1):115-27 [12441135.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):397-407 [12728273.001]
  • (PMID = 20846391.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase
  • [Other-IDs] NLM/ PMC2949806
  •  go-up   go-down


12. Jiang X, Gillen S, Esposito I, Giese NA, Michalski CW, Friess H, Kleeff J: Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer. Histol Histopathol; 2010 12;25(12):1497-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spectrins are members of the superfamily of F-actin cross linking proteins that are important as scaffolding proteins for protein sorting, cell adhesion, and migration.
  • The aim of the present study was to analyze the expression and localization of beta1-spectrin (SPTBN1) in pancreatic tissues. mRNA levels of SPTBN1 in cultured pancreatic cancer cell lines, as well as in normal pancreatic tissues (n=18), chronic pancreatitis (n=48) and pancreatic cancer tissues (n=66) were analyzed by real time quantitative RT-PCR.
  • In the normal pancreas, SPTBN1 was present in the cytoplasm of normal ductal cells and occasionally in pancreatic acinar and centroacinar cells.
  • In conclusion, reduced SPTBN1 expression correlated with shorter survival of pancreatic cancer patients, suggesting a tumor suppressor function of this gene, as has already been shown for other malignancies of the gastrointestinal tract.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / metabolism. Spectrin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunoblotting. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886430.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / SPTBN1 protein, human; 12634-43-4 / Spectrin
  •  go-up   go-down


13. Chuah KL, Yap WM, Tan HW, Koong HN: Recurrence of pulmonary acinic cell carcinoma. Arch Pathol Lab Med; 2006 Jul;130(7):932-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of pulmonary acinic cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Pathol Lab Med. 2003 Apr;127(4):e216-9 [12683906.001]
  • (PMID = 16831044.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


14. Shapiro NL, Bhattacharyya N: Clinical characteristics and survival for major salivary gland malignancies in children. Otolaryngol Head Neck Surg; 2006 Apr;134(4):631-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Determine presentation and survival rates for malignant pediatric salivary gland neoplasms.
  • METHODS: All cases of malignant neoplasms involving the parotid or submandibular gland in patients ages birth to 18 years were extracted from the Surveillance, Epidemiology, and End Results database (1988-2001).
  • Variables included age, gender, tumor histology, size, follow-up time, and vital status.
  • Mean tumor size was 2.5 cm.
  • Among parotid tumors, there were 44 (43%) mucoepidermoid carcinomas and 35 (34%) acinic cell carcinomas.
  • [MeSH-major] Carcinoma, Acinar Cell / mortality. Carcinoma, Mucoepidermoid / mortality. Salivary Gland Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564387.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Chantranuwat C, Sriuranpong V, Huapai N, Chalermchai T, Leungtaweeboon K, Voravud N, Mutirangura A: Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation. J Med Assoc Thai; 2005 Sep;88 Suppl 4:S322-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGFR mutation played crucial role for responsiveness of non-small cell lung cancers to EGFR tyrosine kinase inhibitors.
  • RESULTS: Gland-forming pattern, including bronchiloloalveolar carcinoma (BAC), well-formed acinar, and poorly-formed acinar patterns more frequently contains EGFR mutations than solid pattern (72.7% vs. 23.1%, p = 0.002).
  • CONCLUSION: High frequency of the mutation does not present only in BAC pattern, but also in well-formed and poorly-formed acinar patterns, suggesting them as usual spectrum of EGFR mutated adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Genes, erbB-1 / genetics. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623049.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


16. Epstein JI: An update of the Gleason grading system. J Urol; 2010 Feb;183(2):433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The grading of variants and subtypes of acinar adenocarcinoma of the prostate, including cancer with vacuoles, foamy gland carcinoma, ductal adenocarcinoma, pseudohyperplastic carcinoma and small cell carcinoma have also been modified.
  • For needle biopsy with different cores showing different grades, the current recommendation is to report the grades of each core separately, whereby the highest grade tumor is selected as the grade of the entire case to determine treatment, regardless of the percent involvement.
  • [MeSH-major] Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20006878.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


17. Tanaka H, Fukamachi K, Futakuchi M, Alexander DB, Long N, Tamamushi S, Minami K, Seino S, Ohara H, Joh T, Tsuda H: Mature acinar cells are refractory to carcinoma development by targeted activation of Ras oncogene in adult rats. Cancer Sci; 2010 Feb;101(2):341-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature acinar cells are refractory to carcinoma development by targeted activation of Ras oncogene in adult rats.
  • When adenovirus with Cre recombinase under the control of the CMV enhancer/chicken beta-actin (CAG) promoter (Ad-CAG-Cre) is injected into the pancreatic duct of these animals, pancreatic neoplasias develop.
  • Pathologically, the origin of these lesions is duct, intercalated duct, and centroacinar cells, but not acinar cells.
  • The present study was undertaken to test the effect of acinar cell-specific oncogenic ras expression.
  • Adult transgenic rats were injected with adenovirus with Cre recombinase under the control of the acinar cell-specific promoters amylase (Ad-Amy-Cre) and elastase-1 (Ad-Ela-Cre) or under the control of the non-specific CAG promoter.
  • Injection of either Ad-Amy-Cre or Ad-Ela-Cre into the pancreatic ducts of transgenic animals in which oncogenic Kras is tagged with hemagglutinin (HA), HA-Kras(G12V) rats resulted in expression of oncogenic ras in acinar cells but not in duct, intercalated duct, or centroacinar cells.
  • These results indicate that adult acinar cells are refractory to Ras oncogene activation and do not develop neoplasia in this model.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / etiology. Genes, ras. Pancreas, Exocrine / pathology. Pancreatic Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917056.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


18. Cheng L, Xu JW, Teng XD: [Histologic variants of prostate cancer]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):495-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinosarcoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Acinar Cell / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Endometrioid / pathology. Carcinoma, Small Cell / pathology. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781207.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Sanati S, Watson MA, Salavaggione AL, Humphrey PA: Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol; 2009 Oct;22(10):1273-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.
  • Ductal adenocarcinoma is an uncommon variant of prostatic adenocarcinoma with a generally more aggressive clinical course than usual acinar adenocarcinoma.
  • However, the molecular distinction between ductal and acinar adenocarcinomas is not well characterized.
  • The aim of this investigation was to evaluate the relatedness of ductal versus acinar prostatic adenocarcinoma by comparative gene expression profiling.
  • Archived, de-identified, snap frozen tumor tissue from 5 ductal adenocarcinomas, 3 mixed ductal-acinar adenocarcinomas, and 11 acinar adenocarcinomas cases were analyzed.
  • All cases of acinar and ductal adenocarcinomas were matched by Gleason grade.
  • RNA from whole tissue sections of the 5 ductal and 11 acinar adenocarcinomas cases were subjected to gene expression profiling on Affymetrix U133Plus2 microarrays.
  • Independently, laser-capture microdissection was also performed on the three mixed ductal-acinar cases and five pure acinar cases to isolate homogeneous populations of ductal and acinar carcinoma cells from the same tumor.
  • Seven of these laser-capture microdissected samples (three ductal and four acinar cell populations) were similarly analyzed on U133Plus2 arrays.
  • Analysis of data from whole sections of ductal and acinar carcinomas identified only 25 gene transcripts whose expression was significantly and at least two-fold different between ductal and acinar adenocarcinomas.
  • A similar analysis of microdissected cell populations identified 10 transcripts, including the prolactin receptor, with more significant differences in expression of 5- to 27-fold between ductal and acinar adenocarcinomas cells.
  • Overexpression of prolactin receptor protein in ductal versus acinar adenocarcinoma was confirmed by immunohistochemistry in an independent set of tumors.
  • We conclude that ductal and acinar adenocarcinomas of the prostate are strikingly similar at the level of gene expression.
  • However, several of the genes identified in this study, including the prolactin receptor, represent targets for further investigations on the molecular basis for histomorphological and clinical behavioral differences between acinar and ductal adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Acinar Cell / genetics. Carcinoma, Ductal / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Cluster Analysis. Humans. Immunohistochemistry. Male. Microdissection. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Prostatectomy. RNA, Messenger / analysis. Receptors, Prolactin / analysis. Receptors, Prolactin / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633648.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Prolactin
  •  go-up   go-down


20. Johnykutty S, Miller CH, Hoda RS, Giampoli EJ: Fine-needle aspiration of dedifferentiated acinic cell carcinoma: Report of a case with cyto-histological correlation. Diagn Cytopathol; 2009 Oct;37(10):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of dedifferentiated acinic cell carcinoma: Report of a case with cyto-histological correlation.
  • Dedifferentiated Acinic Cell Carcinoma (DAcCC) is a rare salivary gland malignancy.
  • [MeSH-major] Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Cell Differentiation. Female. Humans. Lymphatic Metastasis / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19526576.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Chiang CP, Wu CW, Lee SP, Chung CC, Wang CW, Lee SL, Nieh S, Yin SJ: Expression pattern, ethanol-metabolizing activities, and cellular localization of alcohol and aldehyde dehydrogenases in human pancreas: implications for pathogenesis of alcohol-induced pancreatic injury. Alcohol Clin Exp Res; 2009 Jun;33(6):1059-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ADH1B was detected in the acinar cells and ADH1C in the ductular, islet, and stellate cells.
  • CONCLUSIONS: Alcohol dehydrogenase and ALDH family members are differentially expressed in the various cell types of pancreas.
  • [MeSH-major] Alcohol Dehydrogenase / metabolism. Aldehyde Dehydrogenase / metabolism. Central Nervous System Depressants / metabolism. Ethanol / metabolism. Pancreas / enzymology. Pancreatic Neoplasms / enzymology. Pancreatitis / enzymology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382905.001).
  • [ISSN] 1530-0277
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Isoenzymes; 3K9958V90M / Ethanol; EC 1.1.1.1 / ADH1B protein, human; EC 1.1.1.1 / ADH1C protein, human; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / ALDH2 protein, human; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


22. Itoh M, Nelson CM, Myers CA, Bissell MJ: Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells. Cancer Res; 2007 May 15;67(10):4759-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maintenance of apico-basal polarity in normal breast epithelial acini requires a balance between cell proliferation, cell death, and proper cell-cell and cell-extracellular matrix signaling.
  • Aberrations in any of these processes can disrupt tissue architecture and initiate tumor formation.
  • Here, we show that the small GTPase Rap1 is a crucial element in organizing acinar structure and inducing lumen formation.
  • Expression of dominant-negative Rap1 resulted in phenotypic reversion of T4-2 cells, led to the formation of acinar structures with correct polarity, and dramatically reduced tumor incidence despite the persistence of genomic abnormalities and baseline growth.
  • Thus, Rap1 acts as a central regulator of breast architecture, with normal levels of activation instructing polarity during acinar morphogenesis, and increased activation inducing tumor formation and progression to malignancy.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1151-8 [10725328.001]
  • [Cites] EMBO J. 1997 Jan 15;16(2):252-9 [9029146.001]
  • [Cites] J Virol. 2001 May;75(9):4459-66 [11287601.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):11804-11 [11278453.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 May;2(5):369-77 [11331911.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Science. 2002 Feb 15;295(5558):1285-8 [11847339.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Oncogene. 1997 Sep 25;15(13):1611-6 [9380414.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):622-6 [9560161.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7475-9 [9636174.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 [9843973.001]
  • [Cites] J Cell Physiol. 1999 Nov;181(2):304-11 [10497309.001]
  • [Cites] Curr Opin Cell Biol. 2005 Apr;17(2):123-8 [15780587.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4591-601 [15899862.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):8-19 [16170364.001]
  • [Cites] Dev Cell. 2006 Jan;10(1):117-26 [16399083.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:343-56 [16869771.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7880-8 [16912161.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):906-20 [15199110.001]
  • [Cites] Nat Immunol. 2002 Mar;3(3):251-8 [11836528.001]
  • [Cites] Nat Rev Genet. 2002 Jul;3(7):513-23 [12094229.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25715-21 [11994301.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1494-503 [12359858.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):195-200 [12469204.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] J Virol. 2003 Jan;77(2):1614-20 [12502878.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):521-6 [12522268.001]
  • [Cites] Cell. 2003 Mar 7;112(5):673-84 [12628187.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):766-74 [12700771.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):417-27 [12707305.001]
  • [Cites] Trends Biochem Sci. 2003 May;28(5):267-75 [12765839.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):55-65 [12892713.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] J Biochem. 2003 Oct;134(4):479-84 [14607972.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):753-62 [14644202.001]
  • [Cites] J Cell Biol. 2004 Feb 16;164(4):603-12 [14769856.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3438-43 [14993595.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12286-92 [14709549.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):865-73 [15177034.001]
  • [Cites] J Hum Genet. 2004;49(6):290-5 [15138850.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6690-700 [15254236.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):111-22 [15479739.001]
  • [Cites] Cell. 1989 Jan 13;56(1):77-84 [2642744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] N Engl J Med. 1994 Jun 2;330(22):1580-8 [8177249.001]
  • [Cites] Science. 1995 Feb 10;267(5199):891-3 [7531366.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1065-73 [10880549.001]
  • (PMID = 17510404.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA064786; United States / NCI NIH HHS / CA / CA64786; United States / NCI NIH HHS / CA / CA064786-07; United States / NCI NIH HHS / CA / R01 CA064786; United States / NCI NIH HHS / CA / R01 CA064786-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.6.5.2 / rap1 GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS160537; NLM/ PMC2841018
  •  go-up   go-down


23. Yoon WJ, Lee JK, Lee KH, Ryu JK, Kim YT, Yoon YB: Cystic neoplasms of the exocrine pancreas: an update of a nationwide survey in Korea. Pancreas; 2008 Oct;37(3):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic neoplasms of the exocrine pancreas: an update of a nationwide survey in Korea.
  • OBJECTIVE: The purpose of this study was to update a previous study of cystic neoplasms of the pancreas (PCNs) conducted in Korea by the authors.
  • RESULTS: A total of 1064 pathologically confirmed PCNs, which consisted of the following diagnoses, were collected: intraductal papillary mucinous neoplasm (IPMN), 436; mucinous cystic neoplasm (MCN), 268; solid pseudopapillary neoplasm (SPN), 195; serous cystic neoplasm (SCN), 162; acinar cell cystic neoplasm 2; and mature teratoma, 1.
  • CONCLUSIONS: Intraductal papillary mucinous neoplasms were the most common PCN observed in Korea.
  • Solid pseudopapillary neoplasms were observed more frequently than those in studies from western countries.
  • [MeSH-major] Cystadenocarcinoma / epidemiology. Cystadenoma / epidemiology. Pancreas, Exocrine / pathology. Pancreatic Neoplasms / epidemiology. Teratoma / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815545.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Khanna AK, Yadav SK, Dixit VK, Kumar M: AgNOR count and subjective AgNOR pattern assessment (SAPA) score in carcinoma of the pancreatic head including periampullary tumors. JOP; 2005 Nov;6(6):575-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: Patients were studied for the AgNOR count and the SAPA score, and the values were correlated with the size of the tumor, the type of tumor and histological type and grade of tumor.
  • Well-differentiated carcinomas had significantly lower AgNOR counts as compared to other tumors except acinar cell carcinomas since acinar cell carcinomas are also well-differentiated tumors.
  • The SAPA score was also higher in moderately-differentiated tumors and the difference between moderately-differentiated tumor and other types of tumors was significant although there was no significant difference between cystadenocarcinomas and unclassified tumors, and between acinar cell carcinomas and well-differentiated tumors on SAPA scoring.
  • CONCLUSIONS: The values of the AgNOR count and the SAPA score are well-correlated with the size of the tumor, the type of tumor and the histological grade.
  • [MeSH-major] Antigens, Nuclear. Nuclear Proteins. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cell Count. Female. Humans. Male. Middle Aged. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286708.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


25. Hasegawa M, Hagiwara S, Sato T, Jijiwa M, Murakumo Y, Maeda M, Moritani S, Ichihara S, Takahashi M: CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int; 2007 May;57(5):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CD109 gene encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface protein.
  • The anti-CD109 antibody generated by the authors was available for formalin-fixed paraffin section, and it strongly stained myoepithelial cells and basal cells but not ductal, acinar, and secretory cells in these glands.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Blotting, Western. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line. Cell Line, Tumor. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Lacrimal Apparatus / chemistry. Lacrimal Apparatus / cytology. Male. Mammary Glands, Human / chemistry. Mammary Glands, Human / cytology. Prostate / chemistry. Prostate / cytology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. RNA Interference. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Salivary Glands / chemistry. Salivary Glands / cytology. Transfection

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493171.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / CD109 protein, human; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Park KS, Lim JW, Kim H: Inhibitory mechanism of omega-3 fatty acids in pancreatic inflammation and apoptosis. Ann N Y Acad Sci; 2009 Aug;1171:421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, we found that reactive oxygen species mediate inflammatory cytokine expression and apoptosis of pancreatic acinar cells stimulated with cerulein.
  • In the present study, we investigated whether omega-3 fatty acids inhibit cytokine expression in cerulein-stimulated pancreatic acinar cells and whether omega-3 fatty acids suppress apoptotic cell death in pancreatic acinar cells exposed to hydrogen peroxide.
  • We found that omega-3 fatty acids, such as docosahexaenoic acid (DHA) and alpha-linolenic acid (ALA), suppressed the expression of inflammatory cytokines (IL-1beta, IL-6) and inhibited the activation of transcription factor activator protein-1 in cerulein-stimulated pancreatic acinar cells.
  • DHA and ALA inhibited DNA fragmentation, inhibited the decrease in cell viability, and inhibited the expression of apoptotic genes (p53, Bax, apoptosis-inducing factor) induced by hydrogen peroxide in pancreatic acinar cells.
  • In conclusion, omega-3 fatty acids may be beneficial for preventing oxidative stress-induced pancreatic inflammation and apoptosis by inhibiting inflammatory cytokine and apoptotic gene expression of pancreatic acinar cells.
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. Ceruletide / pharmacology. DNA Fragmentation / drug effects. Docosahexaenoic Acids / pharmacology. Dose-Response Relationship, Drug. Electrophoretic Mobility Shift Assay. Gene Expression / drug effects. Hydrogen Peroxide / pharmacology. Inflammation / genetics. Inflammation / metabolism. Inflammation / pathology. Interleukin-1beta / genetics. Interleukin-1beta / metabolism. Interleukin-6 / genetics. Interleukin-6 / metabolism. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Protein Binding. Rats. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factor AP-1 / genetics. Transcription Factor AP-1 / metabolism. Tumor Suppressor Protein p53 / metabolism. alpha-Linolenic Acid / pharmacology. bcl-2-Associated X Protein / metabolism


27. Salla C, Chatzipantelis P, Konstantinou P, Karoumpalis I, Pantazopoulou A, Dappola V: Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of solid pseudopapillary tumor of the pancreas: a case report and literature review. World J Gastroenterol; 2007 Oct 14;13(38):5158-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of solid pseudopapillary tumor of the pancreas: a case report and literature review.
  • We describe the clinical, imaging and cytopathological features of solid pseudopapillary tumor of the pancreas (SPTP) diagnosed by endoscopic ultrasound-guided (EUS-guided) fine-needle aspiration (FNA).
  • EUS findings, cytomorphologic features and immunostains of cell block help distinguish SPTP from pancreatic endocrine tumors, acinar cell carcinoma and papillary mucinous carcinoma.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adolescent. Biopsy, Fine-Needle / methods. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Diagnosis, Differential. Endosonography / methods. Female. Humans. Pancreas / pathology. Pancreas / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876886.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 59
  • [Other-IDs] NLM/ PMC4434650
  •  go-up   go-down


28. Redman RS: On approaches to the functional restoration of salivary glands damaged by radiation therapy for head and neck cancer, with a review of related aspects of salivary gland morphology and development. Biotech Histochem; 2008 Jun;83(3-4):103-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The acinar cells are responsible for most of the fluid and organic material in saliva, while the larger ducts influence the inorganic content.
  • It is likely that some, if not many, acinar cells may de-differentiate into intercalated duct-like cells and thus add to the pool of progenitor cells in such situations.
  • If the stress is heavy doses of radiation, however, the result is not only the death of acinar cells, but also a marked decline in functional differentiation and proliferative capacity of all of the surviving cells, including those with progenitor capability.
  • Restoration of gland function, therefore, seems to require increasing the secretory capacity of the surviving cells, or replacing the acinar cells and their progenitors either in the existing gland remnants or with artificial glands.

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Oral Biol. 2000 Oct;45(10):911-9 [10973565.001]
  • [Cites] Anat Embryol (Berl). 1991;184(4):331-5 [1835320.001]
  • [Cites] Biochim Biophys Acta. 1975 Feb 27;379(2):562-70 [1122303.001]
  • [Cites] Am J Anat. 1975 Jun;143(2):201-17 [1146704.001]
  • [Cites] Dev Biol. 1975 Mar;43(1):123-39 [1149921.001]
  • [Cites] J Biol Chem. 1992 Feb 5;267(4):2679-87 [1370829.001]
  • [Cites] J Oral Pathol Med. 1992 Mar;21(3):134-7 [1583597.001]
  • [Cites] Spec Care Dentist. 1991 Nov-Dec;11(6):252-5 [1813995.001]
  • [Cites] Differentiation. 1992 Nov;51(3):225-32 [1281129.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):41-7 [8416881.001]
  • [Cites] J Anat. 1992 Oct;181 ( Pt 2):249-58 [1295863.001]
  • [Cites] Anat Rec. 1993 Apr;235(4):611-21 [8385424.001]
  • [Cites] Arch Histol Cytol. 1993 Jun;56(2):199-206 [8373661.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(3-4):495-502 [8374003.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(3-4):517-24 [8374005.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(3-4):525-30 [8374006.001]
  • [Cites] Microsc Res Tech. 1993 Sep 1;26(1):57-74 [8219375.001]
  • [Cites] J Histochem Cytochem. 1994 Feb;42(2):185-96 [8288864.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jan;77(1):27-35 [7906408.001]
  • [Cites] J Oral Pathol Med. 1993 Nov;22(10):440-6 [7907370.001]
  • [Cites] Microsc Res Tech. 1994 Jan 1;27(1):1-24 [8155902.001]
  • [Cites] Microsc Res Tech. 1994 Jan 1;27(1):25-45 [8155903.001]
  • [Cites] Differentiation. 1994 Apr;56(1-2):75-82 [8026649.001]
  • [Cites] Okajimas Folia Anat Jpn. 1994 Mar;70(6):255-60 [8041560.001]
  • [Cites] Radiat Res. 1994 Nov;140(2):257-65 [7938475.001]
  • [Cites] Histochem J. 1994 Aug;26(8):630-40 [7982787.001]
  • [Cites] Radiat Res. 1995 Feb;141(2):176-82 [7838956.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1994 Dec;30A(12):833-42 [7894774.001]
  • [Cites] Anat Rec. 1995 Apr;241(4):529-40 [7604968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):297-305 [7545658.001]
  • [Cites] Okajimas Folia Anat Jpn. 1995 May;72(1):13-28 [7566876.001]
  • [Cites] J Histochem Cytochem. 1995 Dec;43(12):1203-15 [8537636.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1995 Oct;7(10):928-32 [8590136.001]
  • [Cites] Hum Gene Ther. 1996 Jun 10;7(9):1085-93 [8773510.001]
  • [Cites] J Cell Sci. 1996 Aug;109 ( Pt 8):2013-21 [8856497.001]
  • [Cites] Arch Oral Biol. 1996 Aug-Sep;41(8-9):769-77 [9022914.001]
  • [Cites] Crit Rev Oral Biol Med. 1997;8(1):51-75 [9063625.001]
  • [Cites] Cell Tissue Res. 1997 May;288(2):371-9 [9082973.001]
  • [Cites] Anat Rec. 1997 Jul;248(3):325-31 [9214549.001]
  • [Cites] Arch Histol Cytol. 1997 Jun;60(2):185-93 [9232182.001]
  • [Cites] Arch Oral Biol. 1997 Jun;42(6):443-54 [9382709.001]
  • [Cites] Biochem J. 1998 Feb 15;330 ( Pt 1):437-44 [9461541.001]
  • [Cites] Anat Rec. 1998 Feb;250(2):190-8 [9489780.001]
  • [Cites] Ann N Y Acad Sci. 1998 Apr 15;842:42-8 [9599292.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jun;85(6):699-706 [9638704.001]
  • [Cites] J Dent Res. 1998 Jul;77(7):1504-14 [9663435.001]
  • [Cites] Histochem Cell Biol. 1998 Jul;110(1):81-8 [9681693.001]
  • [Cites] Anat Rec. 1998 Nov;252(3):485-97 [9811227.001]
  • [Cites] Eur J Morphol. 1998 Aug;36 Suppl:50-4 [9825893.001]
  • [Cites] Ultrastruct Pathol. 1998 Nov-Dec;22(6):431-7 [9891921.001]
  • [Cites] Radiat Res. 1999 Feb;151(2):150-8 [9952299.001]
  • [Cites] Arch Histol Cytol. 1998 Dec;61(5):417-26 [9990425.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1916-21 [10068664.001]
  • [Cites] J Cell Physiol. 1998 Dec;177(4):628-35 [10092215.001]
  • [Cites] Anat Rec. 1999 Mar;254(3):408-17 [10096673.001]
  • [Cites] In Vitro Cell Dev Biol. 1986 Aug;22(8):469-80 [2426245.001]
  • [Cites] J Mol Biol. 1986 Dec 5;192(3):567-76 [3560226.001]
  • [Cites] Annu Rev Nutr. 1987;7:423-40 [3038154.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Jul;23(7):465-73 [3610944.001]
  • [Cites] J Dent Res. 1987 Oct;66(10):1559-62 [3476554.001]
  • [Cites] Anat Rec. 1987 Aug;218(4):373-9, 392-3 [3662040.001]
  • [Cites] Dev Biol. 1988 Feb;125(2):265-79 [2828136.001]
  • [Cites] J Pathol. 1987 Dec;153(4):333-44 [3430235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1067-71 [10863080.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Aug;279(2):C286-94 [10912994.001]
  • [Cites] J Histochem Cytochem. 2000 May;48(5):695-8 [10769053.001]
  • [Cites] Coron Artery Dis. 2006 May;17(3):275-81 [16728879.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jun;101(6):753-6 [16731395.001]
  • [Cites] J Dent Res. 2006 Jul;85(7):608-11 [16798859.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] J Oral Pathol Med. 2001 Jan;30(1):29-34 [11140897.001]
  • [Cites] Tissue Cell. 2000 Dec;32(6):457-63 [11197228.001]
  • [Cites] Oral Oncol. 2001 Jan;37(1):84-93 [11120488.001]
  • [Cites] J Gene Med. 2001 Jan-Feb;3(1):82-90 [11269339.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5221-8 [11326699.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] Anat Rec. 2001 Jun 1;263(2):202-14 [11360236.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1055-63 [11592779.001]
  • [Cites] J Histochem Cytochem. 2001 Dec;49(12):1557-64 [11724903.001]
  • [Cites] Anat Rec. 2002 Jan 1;266(1):30-42 [11748569.001]
  • [Cites] Blood. 2002 Feb 1;99(3):850-5 [11806986.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1196-203; discussion 1203-4 [11846913.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2037-44 [11877277.001]
  • [Cites] N Engl J Med. 2002 Mar 7;346(10):738-46 [11882729.001]
  • [Cites] Crit Rev Oral Biol Med. 2000;11(2):199-215 [12002815.001]
  • [Cites] Crit Rev Oral Biol Med. 2000;11(2):216-29 [12002816.001]
  • [Cites] Oral Dis. 2002 May;8(3):141-6 [12108758.001]
  • [Cites] Tissue Eng. 2002 Aug;8(4):649-59 [12202004.001]
  • [Cites] Oral Dis. 2002 Jul;8(4):183-91 [12206399.001]
  • [Cites] Tissue Cell. 2002 Oct;34(5):297-304 [12270256.001]
  • [Cites] Biotech Histochem. 2002 Jul;77(4):189-200 [12503728.001]
  • [Cites] J Oral Pathol Med. 2003 Feb;32(2):90-4 [12542831.001]
  • [Cites] Lancet. 2003 Mar 29;361(9363):1084-8 [12672312.001]
  • [Cites] Thyroid. 2003 Mar;13(3):265-71 [12729475.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(3):199-212 [12799323.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(3):213-25 [12799324.001]
  • [Cites] Biochem Soc Trans. 2003 Aug;31(Pt 4):777-80 [12887304.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):305-10 [12893079.001]
  • [Cites] J Oral Pathol Med. 2004 Jan;33(1):23-9 [14675137.001]
  • [Cites] Pancreatology. 2003;3(6):487-96 [14673200.001]
  • [Cites] Caries Res. 2004 May-Jun;38(3):241-6 [15153695.001]
  • [Cites] Caries Res. 2004 May-Jun;38(3):247-53 [15153696.001]
  • [Cites] J Morphol. 1965 Nov;117(3):295-352 [5883925.001]
  • [Cites] Pflugers Arch Gesamte Physiol Menschen Tiere. 1966;291(1):99-106 [5229603.001]
  • [Cites] Exp Cell Res. 1967 Sep;47(3):536-44 [6054025.001]
  • [Cites] Lab Invest. 1969 Mar;20(3):230-3 [5773216.001]
  • [Cites] Arch Biochem Biophys. 1970 Apr;137(2):325-39 [4985719.001]
  • [Cites] J Oral Surg. 1970 Jun;28(6):432-7 [5266462.001]
  • [Cites] Proc Soc Exp Biol Med. 1970 May;134(1):98-102 [5423538.001]
  • [Cites] Anat Rec. 1970 Aug;167(4):489-95 [4393908.001]
  • [Cites] J Cell Biol. 1970 Jul;46(1):81-7 [5459013.001]
  • [Cites] J Embryol Exp Morphol. 1970 Sep;24(2):411-24 [4250039.001]
  • [Cites] J Ultrastruct Res. 1971 Feb;34(3):276-87 [4926049.001]
  • [Cites] Am J Anat. 1971 Feb;130(2):195-207 [5547002.001]
  • [Cites] Anat Rec. 1971 Apr;169(4):679-96 [4102246.001]
  • [Cites] J Anat. 1971 Apr;108(Pt 3):409-17 [5575309.001]
  • [Cites] Dev Biol. 1988 Oct;129(2):464-75 [3046963.001]
  • [Cites] J Histochem Cytochem. 1989 Apr;37(4):515-28 [2926128.001]
  • [Cites] J Anat. 1988 Dec;161:143-51 [3254887.001]
  • [Cites] Arch Oral Biol. 1989;34(7):499-506 [2597043.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Jan;26(1):33-43 [1689711.001]
  • [Cites] J Dent Res. 1989 Jul;68(7):1138-45 [2483725.001]
  • [Cites] Dev Biol. 1990 Jun;139(2):370-82 [2338173.001]
  • [Cites] J Histochem Cytochem. 1990 Jul;38(7):941-7 [2113069.001]
  • [Cites] Br J Plast Surg. 1990 Jul;43(4):437-9 [2393769.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Dec;70(6):724-9 [2263329.001]
  • [Cites] Am J Anat. 1991 Jun;191(2):167-84 [1677796.001]
  • [Cites] In Vitro Cell Dev Biol. 1991 Sep;27A(9):707-12 [1717429.001]
  • [Cites] J Histochem Cytochem. 1991 Dec;39(12):1693-706 [1940321.001]
  • [Cites] Dev Biol. 1975 Mar;43(1):140-58 [1171033.001]
  • [Cites] Anat Rec. 1975 May;182(1):29-39 [1155788.001]
  • [Cites] Arch Histol Jpn. 1975 Oct;38(3):177-208 [1203025.001]
  • [Cites] J Dent Res. 1976 Jul-Aug;55(4):712 [1064629.001]
  • [Cites] J Nutr. 1976 Sep;106(9):1295-306 [956913.001]
  • [Cites] J Dent Res. 1977 Feb;56(2):177-80 [264884.001]
  • [Cites] J Anat. 1978 Sep;127(Pt 1):181-91 [701194.001]
  • [Cites] Am J Anat. 1978 Nov;153(3):367-89 [707321.001]
  • [Cites] J Dent Res. 1978 Jul-Aug;57(7-8):826-33 [281355.001]
  • [Cites] J Dent Res. 1978 Sep-Oct;57(9-10):915-6 [281368.001]
  • [Cites] Pediatr Res. 1979 May;13(5 Pt 1):615-22 [382069.001]
  • [Cites] Anat Rec. 1979 Nov;195(3):431-42 [507399.001]
  • [Cites] Am J Anat. 1979 Dec;156(4):543-65 [525627.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1980 Mar;49(3):233-6 [6928308.001]
  • [Cites] Arch Histol Jpn. 1979 Oct;42(4):427-44 [575618.001]
  • [Cites] Genetics. 1980 May;95(1):129-41 [6159249.001]
  • [Cites] Acta Anat (Basel). 1979;105(4):431-8 [552784.001]
  • [Cites] Am J Anat. 1980 Jul;158(3):299-320 [7446434.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;391(3):291-9 [7281495.001]
  • [Cites] J Electron Microsc (Tokyo). 1981;30(1):29-45 [7288348.001]
  • [Cites] Anat Rec. 1981 Nov;201(3):499-511 [7305031.001]
  • [Cites] Exp Cell Res. 1982 Feb;137(2):481-5 [7035204.001]
  • [Cites] J Oral Pathol. 1982 Feb;11(1):1-17 [6801238.001]
  • [Cites] Mol Cell Biochem. 1982 Jun 11;45(2):83-99 [6810092.001]
  • [Cites] Arch Oral Biol. 1982;27(5):367-75 [6956249.001]
  • [Cites] Kidney Int. 1983 Feb;23(2):350-7 [6842960.001]
  • [Cites] Anat Rec. 1983 May;206(1):11-21 [6881548.001]
  • [Cites] Eur J Cell Biol. 1984 Jan;33(1):112-22 [6698033.001]
  • [Cites] Gastroenterology. 1984 Jul;87(1):103-8 [6609862.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(4):443-60 [6145251.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;404(2):187-96 [6207660.001]
  • [Cites] Histochem J. 1985 Jun;17(6):665-74 [4030396.001]
  • [Cites] Arch Biochem Biophys. 1964 Aug;107:197-208 [14224825.001]
  • [Cites] J Am Dent Assoc. 1965 Apr;70:868-83 [14257519.001]
  • [Cites] Nature. 1960 Jun 4;186:784-8 [14415026.001]
  • [Cites] J Anat. 1959 Jul;93:287-95 [14415247.001]
  • [Cites] Am J Physiol. 1960 Apr;198:771-3 [14443285.001]
  • [Cites] Cell Transplant. 2004;13(6):691-9 [15648739.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 18):29-36 [15726520.001]
  • [Cites] Tissue Eng. 2005 Jan-Feb;11(1-2):172-81 [15738672.001]
  • [Cites] Plast Reconstr Surg. 2005 Jun;115(7):1973-85 [15923846.001]
  • [Cites] Int J Exp Pathol. 2006 Feb;87(1):41-8 [16436112.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1804-12 [16551865.001]
  • [Cites] Arch Oral Biol. 2006 May;51(5):351-8 [16274660.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1241-6 [16631879.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2006 May;288(5):498-526 [16612829.001]
  • [Cites] Periodontol 2000. 2006;41:218-23 [16686936.001]
  • [Cites] Int J Exp Pathol. 1998 Oct;79(5):293-301 [10193312.001]
  • [Cites] J Orthop Res. 1999 Mar;17(2):286-92 [10221847.001]
  • [Cites] Anat Rec. 1999 Jun 1;255(2):155-61 [10359516.001]
  • [Cites] Biomaterials. 1999 Jun;20(11):1043-9 [10378804.001]
  • [Cites] Anat Rec. 1999 Sep 1;256(1):72-7 [10456987.001]
  • [Cites] J Dent Res. 1957 Dec;36(6):866-79 [13481222.001]
  • [Cites] J Anat. 1959 Apr;93(2):201-16 [13641119.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1961;Suppl 149:1-84 [13682405.001]
  • [Cites] Cancer. 1986 Mar 1;57(5):1011-8 [3002591.001]
  • [Cites] Int J Exp Pathol. 1999 Oct;80(5):283-90 [10607019.001]
  • [Cites] Anat Rec. 2000 Mar 1;258(3):269-76 [10705347.001]
  • [Cites] Anat Rec. 2000 Apr 1;258(4):349-58 [10737853.001]
  • [Cites] Arch Oral Biol. 2000 May;45(5):425-30 [10739864.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1758(8):1071-7 [16368071.001]
  • [Cites] Anat Embryol (Berl). 2006 Oct;211(5):567-74 [16937148.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1601-11 [17071584.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2525-34 [17078052.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Jan;51(1):154-61 [17074797.001]
  • [Cites] Oral Oncol. 2007 Feb;43(2):137-42 [16798061.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4928-33 [17699873.001]
  • [Cites] Anat Rec (Hoboken). 2008 Jan;291(1):94-104 [18085625.001]
  • [Cites] Cells Tissues Organs. 2008;187(3):233-42 [17984628.001]
  • [Cites] Br J Radiol. 1959 Sep;32:596-608 [13809698.001]
  • [Cites] J Biol Chem. 1971 Jun 25;246(12):3879-84 [5561465.001]
  • [Cites] Dev Biol. 1971 Jun;25(2):248-79 [5562853.001]
  • [Cites] J Cell Biol. 1971 Nov;51(21):575-9 [4939529.001]
  • [Cites] Eur J Cancer. 1971 Oct;7(5):373-6 [5159870.001]
  • [Cites] Virchows Arch B Cell Pathol. 1972;10(3):253-62 [4113487.001]
  • [Cites] Virchows Arch A Pathol Pathol Anat. 1973 Mar 20;359(1):31-48 [4632998.001]
  • [Cites] Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1973 Apr 30;204(1):27-56 [4699530.001]
  • [Cites] Acta Physiol Lat Am. 1973;23(1):37-50 [4713544.001]
  • [Cites] J Morphol. 1973 Jul;140(3):343-54 [4716826.001]
  • [Cites] Histochem J. 1973 Sep;5(5):463-71 [4752918.001]
  • [Cites] Anat Rec. 1974 Feb;178(2):187-201 [4815292.001]
  • [Cites] Lab Invest. 1974 Jul;31(1):82-9 [4843212.001]
  • [Cites] Lab Invest. 1974 Oct;31(4):340-54 [4412888.001]
  • [Cites] Dev Biol. 1974 Nov;41(1):31-41 [4140120.001]
  • (PMID = 18828044.001).
  • [ISSN] 1473-7760
  • [Journal-full-title] Biotechnic & histochemistry : official publication of the Biological Stain Commission
  • [ISO-abbreviation] Biotech Histochem
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / DE014995-02; United States / NIDCR NIH HHS / DE / R21 DE014995; United States / NIDCR NIH HHS / DE / DE14995; United States / NIDCR NIH HHS / DE / R21 DE014995-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 233
  • [Other-IDs] NLM/ NIHMS125988; NLM/ PMC2740375
  •  go-up   go-down


29. Chen Y, Yu G, Ma D, Ni C, Zhu M: Microadenocarcinoma of the pancreas. Eur J Gastroenterol Hepatol; 2009 Dec;21(12):1373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Microadenocarcinoma (MA) of the pancreas is a rare kind of neoplasm, whose status as an independent tumor entity is still a matter of controversy.
  • Immunohistochemistry revealed that MA, though with a certain extent of epithelial differentiation, possesses a different immunological phenotype from those of ductal carcinoma, acinar cell carcinoma, and endocrine tumors.
  • Genetic analysis showed no abnormality of p53, K-ras, and beta-catenin, which were usually mutated in pancreatic ductal adenocarcinoma.
  • CONCLUSION: Therefore, we suggest that MA should be taken as an independent tumor entity rather than a kind of growth pattern, but a final decision should be reached after cautious differential diagnosis of other kinds of pancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19916245.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Takechi Y, Shinozaki T, Fukuda T, Asami K, Yanagawa T, Takagishi K: Multiple subcutaneous inflammation, osteolysis, and polyarthritis. Skeletal Radiol; 2010 Jun;39(6):601-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arthritis / diagnosis. Carcinoma, Acinar Cell / diagnosis. Dermatitis / diagnosis. Fat Necrosis / diagnosis. Osteolysis / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1968 Jan;68(1):75-87 [5635332.001]
  • [Cites] Am J Med. 1975 Mar;58(3):417-23 [1090161.001]
  • [Cites] Arthritis Rheum. 1973 May-Jun;16(3):388-92 [4708017.001]
  • [Cites] Arthritis Rheum. 1980 Mar;23(3):355-60 [7362688.001]
  • [Cites] Radiology. 1986 Jan;158(1):67-8 [3940400.001]
  • [Cites] Gut. 1990 Aug;31(8):953-5 [2387523.001]
  • [Cites] Clin Rheumatol. 1997 Mar;16(2):199-203 [9093803.001]
  • [Cites] Arthritis Rheum. 1983 Feb;26(2):127-32 [6824511.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Rheumatol. 1993 Aug;20(8):1436-7 [8230036.001]
  • (PMID = 20177674.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Kosmahl M, Pauser U, Anlauf M, Sipos B, Peters K, Lüttges J, Klöppel G: [Cystic pancreas tumors and their classification: features old and new]. Pathologe; 2005 Feb;26(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic tumors and tumor-like lesions of the pancreas are rare, but have attracted a great deal of attention because they are easily recognized with new imaging methods and, in contrast to ductal adenocarcinoma, they can usually be cured surgically.
  • Known entities have been better characterized (i.e. solid pseudopapillary neoplasm, intraductal papillary mucinous neoplasm) and new ones described (serous oligocystic adenoma, mucinous non-neoplastic cyst, acinar cell cystadenoma and cystic hamartoma).
  • This review discusses the most important cystic tumors and tumor-like lesions, presents a new classification, and summarizes the immunohistochemical differential diagnosis.
  • [MeSH-major] Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):113-5 [12004359.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):187-9 [9504865.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2150-8 [9610694.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):154-8 [11850544.001]
  • [Cites] Ann Surg. 1978 Nov;188(5):679-84 [718294.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):31-42 [10721805.001]
  • [Cites] Virchows Arch. 1994;424(1):13-7 [7526946.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Arch Pathol Lab Med. 2002 Feb;126(2):229-30 [11825129.001]
  • [Cites] Mod Pathol. 2002 May;15(5):492-501 [12011254.001]
  • [Cites] Hum Pathol. 1992 Nov;23(11):1309-12 [1427759.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):698-704 [12023573.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Gastroenterology. 1990 Jun;98(6):1655-65 [1692551.001]
  • [Cites] Pancreas. 2000 Jul;21(1):104-5 [10881942.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):16-30 [10721804.001]
  • [Cites] Pancreas. 1996 May;12(4):419-21 [8740414.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):7-15 [10721803.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):1-6 [10721802.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Int Surg. 2000 Jan-Mar;85(1):67-70 [10817436.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):211-4 [12162680.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Acta Pathol Jpn. 1991 Dec;41(12):916-21 [1785350.001]
  • [Cites] Ann Surg. 1975 May;181(5):546-51 [1130873.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):339-46 [15104296.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):317-21 [11141506.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1539-42 [8413476.001]
  • [Cites] Hum Pathol. 1992 Aug;23(8):871-5 [1644432.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1401-5 [8898845.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):6-13 [11499841.001]
  • [Cites] Am J Gastroenterol. 1982 Aug;77(8):576-7 [7102641.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • [Cites] Pathol Res Pract. 1996 Mar;192(3):300-4; discussion 305 [8739477.001]
  • (PMID = 15624092.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 58
  •  go-up   go-down


32. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int; 2008 Nov;102(10):1369-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We review the clinicopathological features of the following unusual histological variants of prostatic carcinoma: small cell carcinoma, ductal adenocarcinoma, sarcomatoid (carcinosarcoma), basal cell, squamous cell and adenosquamous, and urothelial carcinoma.
  • Some develop from acinar adenocarcinoma after hormonal or radiation therapy.
  • Only basal cell carcinoma is seen as a low-grade carcinoma.
  • [MeSH-major] Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Carcinosarcoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793296.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


33. Tanahashi C, Yabuki S, Akamine N, Yatabe Y, Ichihara S: Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman. Pathol Int; 2007 Jan;57(1):43-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman.
  • Acinic cell carcinoma of the breast is an uncommon neoplasm.
  • Reported herein is the first case of primary acinic cell carcinoma of the breast in a Japanese woman.
  • To the naked eye, the tumor appeared well circumscribed and the cut surface was grayish-pink and hemorrhaging.
  • Microscopically, the tumor was predominantly made up of a monotonous proliferation of cells with a finely granular cytoplasm, resembling acinic cells of the parotid gland.
  • In spite of extensive sampling, no common histological patterns of breast carcinoma such as in situ and invasive ductal carcinoma were recognized in the present case, indicating that the present case was pure acinic cell carcinoma.
  • In addition, the immunohistochemical profile of this tumor was identical to that of the acinic cell carcinoma of the salivary gland: estrogen receptor, progesterone receptor, HER2 and cytokeratin (CK)20 were negative and amylase and CK7 were positive.
  • The patient has been well for 22 months since the wide local excision of the tumor and no signs of salivary neoplasm are evident to date.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology


34. Ban D, Shimada K, Sekine S, Sakamoto Y, Kosuge T, Kanai Y, Hiraoka N: Pancreatic ducts as an important route of tumor extension for acinar cell carcinoma of the pancreas. Am J Surg Pathol; 2010 Jul;34(7):1025-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ducts as an important route of tumor extension for acinar cell carcinoma of the pancreas.
  • Acinar cell carcinoma (ACC) of the pancreas is very rare, which usually grows expansively.
  • We reviewed the detailed gross and histologic features of 13 cases of ACC, of which 7 (54%) showed intraductal polypoid growth (IPG) of the tumor in the large pancreatic ducts with a mean IPG length of 24.8 mm.
  • Comparison of the clinicopathologic characteristics showed that ACC with IPG had less infiltrative features including lymphatic, venous, and neural invasion, formation of tumor thrombus in the portal vein, nodal metastasis, and invasion beyond the pancreas to the surrounding organs; death in only 1 case (14%) of ACC with IPG was the result of ACC itself.
  • In contrast, ACC without IPG frequently showed more infiltrative growth, and was the cause of death in 50% of patients with this type of tumor.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Invasiveness. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534994.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Kolb-van Harten P, Rosien U, Klöppel G, Layer P: Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression. Pancreatology; 2007;7(4):370-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression.
  • We report a case of acinar cell carcinoma of the pancreas associated with excessively elevated levels of serum alpha-fetoprotein (>32,000 ng/ml).
  • This regimen was associated with clinical improvement and dramatic decreases in both tumor size and serum alpha-fetoprotein.
  • [MeSH-major] Carcinoma, Acinar Cell / metabolism. Pancreatic Neoplasms / metabolism. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel and IAP
  • (PMID = 17703084.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


36. Tavernier L, Godon A, Algros MP, Rainfaing E, Chobaut JC: [Acinic cell carcinoma in an ectopic salivary gland]. Rev Laryngol Otol Rhinol (Bord); 2010;131(4-5):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma in an ectopic salivary gland].
  • On the occasion of the coverage of a cervical tumefaction in a child, which led to the diagnosis of acinic cell carcinoma of ectopic salivary gland, the authors conducted a literature review of this tumour.
  • From a histological point of view it is difficult to distinguish, if primitive location, the occurrence of the tumour in an ectopic salivary gland, its occurrence in intra-node heterotopic salivary tissue.
  • This one remains empirical and discussed on a case-by-case basis for a malignant tumour that is exceptional in this location and at that age.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Choristoma / pathology. Mandibular Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21866744.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


37. Sullivan CA, Haddad RI, Tishler RB, Mahadevan A, Krane JF: Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope; 2005 Jun;115(6):958-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation-induced cell loss in human submandibular glands.
  • In the chemoradiated glands, light microscopic findings included pronounced acinar cell loss with accompanying ductal metaplasia and ductal proliferation and increased fibrosis, chronic inflammation, nuclear atypia, and cytoplasmic vacuolization when compared with controls.
  • Primary dysfunction in humans appears to be related to a reduction in function and number of submandibular gland acinar cells.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Submandibular Gland / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933500.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Khalili M, Wax BN, Reed WP, Schuss A, Drexler S, Weston SR, Katz DS: Radiology-pathology conference. Acinar cell carcinoma of the pancreas. Clin Imaging; 2006 Sep-Oct;30(5):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology-pathology conference. Acinar cell carcinoma of the pancreas.
  • Acinar cell carcinoma (ACC) is a rare tumor that constitutes 1% of pancreatic neoplasms.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Intestinal Obstruction / diagnosis. Pancreatic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919557.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Smukalla K, Kalinski T, Motsch C: [Distant metastases on acinic cell carcinoma of the parotid gland after 12 years symptom-free interval]. Laryngorhinootologie; 2006 Aug;85(8):586-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distant metastases on acinic cell carcinoma of the parotid gland after 12 years symptom-free interval].
  • Acinic cell carcinoma of parotid gland as cause of distant metastases are rare.
  • The patient was a 60-year-old woman who had in 1993 a acinic cell carcinoma of right parotid gland.
  • Tumour can be resected through total parotidectomy with facial nerve anastomosis and modified radical neck dissection (T (3) N (2b) M (0)).
  • Since the operation the patient has remained symptom-free without any sign of tumour recurrence.
  • Histologically and immunohistochemically the diagnosis of distant metastase on acinic carcinoma of the parotid gland was confirmed.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Manubrium. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Female. Follow-Up Studies. Humans. Middle Aged. Neck Dissection. Neoplasm Staging. Osteolysis / diagnosis. Osteolysis / pathology. Osteolysis / surgery. Parotid Gland / pathology. Parotid Gland / surgery. Radionuclide Imaging. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883494.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Blaine SA, Ray KC, Anunobi R, Gannon MA, Washington MK, Means AL: Adult pancreatic acinar cells give rise to ducts but not endocrine cells in response to growth factor signaling. Development; 2010 Jul;137(14):2289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult pancreatic acinar cells give rise to ducts but not endocrine cells in response to growth factor signaling.
  • Studies in both humans and rodents have found that insulin(+) cells appear within or near ducts of the adult pancreas, particularly following damage or disease, suggesting that these insulin(+) cells arise de novo from ductal epithelium.
  • Therefore, we tested the hypothesis that both hyperplastic ductal cells and their associated insulin(+) cells arise from the same cell of origin.
  • Using a mouse model that develops insulin(+) cell-containing hyperplastic ducts in response to the growth factor TGFalpha, we performed genetic lineage tracing experiments to determine which cells gave rise to both hyperplastic ductal cells and duct-associated insulin(+) cells.
  • We found that hyperplastic ductal cells arose largely from acinar cells that changed their cell fate, or transdifferentiated, into ductal cells.
  • However, insulin(+) cells adjacent to acinar-derived ductal cells arose from pre-existing insulin(+) cells, suggesting that islet endocrine cells can intercalate into hyperplastic ducts as they develop.
  • We conclude that apparent pancreatic plasticity can result both from the ability of acinar cells to change fate and of endocrine cells to reorganize in association with duct structures.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetologia. 2005 Jan;48(1):49-57 [15616797.001]
  • [Cites] Dev Cell. 2009 Dec;17(6):849-60 [20059954.001]
  • [Cites] Pancreas. 2005 Jul;31(1):32-42 [15968245.001]
  • [Cites] Genesis. 2005 Jul;42(3):210-7 [15986486.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Diabetes. 2005 Sep;54(9):2596-601 [16123347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15116-21 [16210247.001]
  • [Cites] Diabetes. 2006 Feb;55(2):269-72 [16361411.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 1;350(4):987-93 [17046717.001]
  • [Cites] Diabetes. 2007 Mar;56(3):634-40 [17327430.001]
  • [Cites] Diabetes. 2008 Nov;57(11):3069-77 [18728229.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19915-9 [19052237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9715-20 [19487660.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1416-26 [10579983.001]
  • [Cites] Diabetologia. 2000 Jul;43(7):907-14 [10952464.001]
  • [Cites] BMC Dev Biol. 2001;1:4 [11299042.001]
  • [Cites] Nature. 2004 May 6;429(6987):41-6 [15129273.001]
  • [Cites] Genesis. 2004 Jul;39(3):186-93 [15282745.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(5):399-405 [2459841.001]
  • [Cites] Pancreas. 1989;4(4):472-85 [2762275.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1121-35 [1693546.001]
  • [Cites] J Clin Invest. 1992 Oct;90(4):1352-60 [1401070.001]
  • [Cites] Genes Dev. 1993 May;7(5):774-86 [7684006.001]
  • [Cites] Development. 1993 May;118(1):33-46 [8104143.001]
  • [Cites] Diabetes. 1993 Dec;42(12):1715-20 [8243817.001]
  • [Cites] Diabetologia. 1995 Dec;38(12):1405-11 [8786013.001]
  • [Cites] J Biol Chem. 1999 Jan 1;274(1):305-15 [9867845.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Diabetes. 1999 Mar;48(3):507-13 [10078550.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):971-7 [17404620.001]
  • [Cites] Dev Cell. 2007 May;12(5):817-26 [17488631.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2553-61 [17786244.001]
  • [Cites] Pancreas. 2007 Oct;35(3):212-7 [17895840.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Cell. 2008 Jan 25;132(2):197-207 [18243096.001]
  • [Cites] Nature. 2008 Oct 2;455(7213):627-32 [18754011.001]
  • [Cites] Gastroenterology. 2009 Nov;137(5):1785-94 [19689925.001]
  • [Cites] Cancer Cell. 2009 Nov 6;16(5):379-89 [19878870.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3401-9 [15769977.001]
  • (PMID = 20534672.001).
  • [ISSN] 1477-9129
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P60 DK020593; United States / NIDDK NIH HHS / DK / NIH P30DK058404; United States / NIDDK NIH HHS / DK / DK58404; United States / NIDDK NIH HHS / DK / P30 DK058404; United States / NICHD NIH HHS / HD / P30 HD015052; United States / NCI NIH HHS / CA / NIH CA68485; United States / NEI NIH HHS / EY / EY08126; United States / NEI NIH HHS / EY / P30 EY008126; United States / NIDDK NIH HHS / DK / DK59637; United States / NIDDK NIH HHS / DK / P30 DK020593; United States / NCI NIH HHS / CA / P30 CA068485; United States / NICHD NIH HHS / HD / HD15052; United States / NIDDK NIH HHS / DK / DK20593; United States / NIDDK NIH HHS / DK / U24 DK059637
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin; 0 / Intercellular Signaling Peptides and Proteins
  • [Other-IDs] NLM/ PMC2889602
  •  go-up   go-down


41. Kobayashi S, Asakura T, Ohike N, Enomoto T, Sakurai J, Koizumi S, Watanabe T, Nakano H, Otsubo T: Mixed acinar-endocrine carcinoma of the pancreas with intraductal growth into the main pancreatic duct: Report of a case. Surg Today; 2010 Apr;40(4):380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed acinar-endocrine carcinoma of the pancreas with intraductal growth into the main pancreatic duct: Report of a case.
  • The patient was a 75-year-old asymptomatic man, in whom a tumor mass in the pancreatic tail had been found 6 months earlier.
  • Computed tomography revealed a mass 7 cm in diameter, and an enhancement with contrast medium was observed at the periphery and partially inside the mass, but not in most parts of the tumor.
  • A distal pancreatectomy was performed because of the possibility of a malignant tumor.
  • The tumor consisted of a lobular invasive growth component and a component with intraductal growth into the main pancreatic duct, and histologically the tumor cells had solid acinar to partially trabecular/tubular patterns.
  • Trypsin (an acinic cell marker) expression was widely observed, followed by the expression of chromogranin A (an endocrine cell marker) in about 30% of the tumor cells.
  • The tumor was diagnosed as mixed acinar-endocrine carcinoma according to the WHO classification.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):249-57 [10952408.001]
  • [Cites] J Clin Gastroenterol. 2000 Sep;31(2):175-8 [10993440.001]
  • [Cites] Surg Today. 2009;39(2):162-7 [19198998.001]
  • [Cites] Pathol Res Pract. 1996 Sep;192(9):901-8 [8950756.001]
  • [Cites] APMIS. 2006 Oct;114(10 ):720-5 [17004975.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):33-40 [16000844.001]
  • [Cites] Surgery. 2008 Aug;144(2):141-8 [18656619.001]
  • [Cites] J Korean Med Sci. 1996 Apr;11(2):188-92 [8835769.001]
  • [Cites] Ultrastruct Pathol. 1993 Sep-Oct;17(5):483-93 [8256293.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):604-7 [10805854.001]
  • [Cites] Pancreas. 2003 Apr;26(3):306-8 [12657959.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] J Gastroenterol. 1998 Oct;33(5):761-5 [9773947.001]
  • [Cites] J Gastroenterol. 1997 Dec;32(6):830-5 [9430026.001]
  • [Cites] Radiographics. 1997 Mar-Apr;17 (2):453-72; quiz 472A-472B [9084084.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3C):2131-4 [11501836.001]
  • (PMID = 20339996.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Chromogranin A
  •  go-up   go-down


42. Lopez-Beltran A, Cheng L, Prieto R, Blanca A, Montironi R: Lymphoepithelioma-like carcinoma of the prostate. Hum Pathol; 2009 Jul;40(7):982-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In one case the diagnosis of lymphoepithelioma-like carcinoma admixed with conventional acinar adenocarcinoma was an unexpected finding at time of transurethral resection for benign prostatic hyperplasia.
  • Microscopically, all tumors contained lymphoepithelioma-like carcinoma, which comprised 10% to 90% of the entire tumor.
  • Morphologic recognition and distinction from other prostatic lesions and tumors with prominent lymphoid stroma is critical for its clinical management.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269013.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Fulciniti F, Losito NS, Ionna F, Longo F, Aversa C, Botti G, Foschini MP: Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation. Diagn Cytopathol; 2010 May;38(5):368-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In line with numerous other pathological analogies between breast and salivary gland lesions, SPA shares with fibrocystic disease of the breast many histopathological features, i.e., fibrosis, oncocytic (apocrine) changes, hyperplasia of ductal and acinar epithelium, cystic dilation of ducts, and, often, atypical epithelial changes.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / pathology. Cysts / pathology. Parotid Gland / pathology. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19937766.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB: Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol; 2009 Sep;22(9):1176-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic variants of prostate carcinoma account for 5-10% of the disease and are typically seen in association with conventional acinar carcinoma.
  • Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma (N=17), ductal adenocarcinoma (N=18), mucinous carcinoma (N=18), and small cell carcinoma (N=7).
  • A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology (N=9), was also investigated.
  • TMPRSS2:ERG fusion was identified in 83% (15/18), 71% (5/7), 50% (9/18), 33% (3/9), and 29% (5/17) of mucinous, small cell, ductal, glomeruloid, and foamy gland prostate carcinomas, respectively.
  • Interestingly, ERG rearrangement in small cell carcinomas occurred exclusively through Edel, supporting the notion that TMPRSS2:ERG with Edel is an aggressive molecular subtype.
  • Notably, 88% (43/49) variant morphologies in this cohort showed concordance of TMPRSS2:ERG fusion with associated conventional acinar type, suggesting that variant morphology is clonally related to the latter.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 1999;1(1):31-5 [11250680.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):152-7 [15101049.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):316-27 [14976541.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Int J Exp Pathol. 2005 Aug;86(4):213-8 [16045543.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Neoplasia. 2007 Mar;9(3):200-6 [17401460.001]
  • [Cites] Mod Pathol. 2007 May;20(5):538-44 [17334343.001]
  • [Cites] J Pathol. 2007 May;212(1):91-101 [17385188.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):781-6 [16901974.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Mod Pathol. 2007 Sep;20(9):921-8 [17632455.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]
  • [Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]
  • [Cites] Urology. 2007 Oct;70(4):630-3 [17991527.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1690-5 [17971772.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):73-80 [18172298.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3094-8 [18451133.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3584-90 [18483239.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):519-28 [18538735.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7629-37 [18794152.001]
  • [Cites] Cancer Metastasis Rev. 2002;21(3-4):381-95 [12549773.001]
  • (PMID = 19465903.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / U01 CA111275-01; United States / NCI NIH HHS / CA / R01 CA102872; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / CA069568-110020; United States / NCI NIH HHS / CA / UO1 CA111275-01; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / SPINK1 protein, human; 0 / TMPRSS2-ERG fusion protein, human; 0 / TMPRSS2-ETV1 fusion protein, human
  • [Other-IDs] NLM/ NIHMS148618; NLM/ PMC2760291
  •  go-up   go-down


45. Carrio M, Arderiu G, Myers C, Boudreau NJ: Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res; 2005 Aug 15;65(16):7177-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model.
  • We previously reported that HoxD10 helps to maintain a quiescent, differentiated phenotype in endothelial cells by suppressing expression of genes involved in remodeling the extracellular matrix and cell migration.
  • Retroviral gene transfer to restore expression of HoxD10 in the malignant breast tumor cells MDA-MB-231 significantly impaired migration, and when these cells were cultured in a three-dimensional laminin-rich basement membrane (3DlrBM) model, they formed polarized, acinar structures.
  • Taken together, our results suggest that HoxD10 has tumor-suppressive functions for mammary epithelial cells.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Cell Communication / genetics. Genes, Tumor Suppressor. Homeodomain Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Animals. Basement Membrane / metabolism. Basement Membrane / pathology. Cell Growth Processes / genetics. Cell Line, Tumor. Cell Movement / genetics. Disease Models, Animal. Disease Progression. Endometrial Neoplasms / genetics. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Extracellular Matrix / genetics. Extracellular Matrix / metabolism. Extracellular Matrix / pathology. Female. HeLa Cells. Humans. Laminin / metabolism. Mice. Mice, Nude. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103068.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 85249
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Laminin; 0 / RNA, Messenger; 0 / Transcription Factors; 145420-66-2 / HOXD10 protein, human
  •  go-up   go-down


46. Lim JW, Song JY, Seo JY, Kim H, Kim KH: Role of pancreatitis-associated protein 1 on oxidative stress-induced cell death of pancreatic acinar cells. Ann N Y Acad Sci; 2009 Aug;1171:545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of pancreatitis-associated protein 1 on oxidative stress-induced cell death of pancreatic acinar cells.
  • Previously we showed that oxidative stress induces apoptosis of pancreatic acinar cells with nuclear loss of DNA repair proteins.
  • In this study, we investigated the role of PAP-1 on oxidative stress-induced cell death of pancreatic acinar AR42J cells.
  • PAP-1 mRNA expression and cell viability were determined.
  • Cell viability decreased with the concentration of glucose oxides delivered to the cells that had received glucose.
  • Cell death caused by oxidative stress was inhibited in the cells transfected with PAP-1 S cDNA, but it increased in the cells transfected with PAP-1 AS cDNA.
  • These results indicate that PAP-1 may be a defensive gene for oxidative stress-induced cell death of pancreatic acinar cells.
  • [MeSH-major] Antigens, Neoplasm / physiology. Apoptosis / physiology. Biomarkers, Tumor / physiology. Lectins, C-Type / physiology. Oxidative Stress / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / physiology. DNA, Antisense / genetics. DNA, Complementary / genetics. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723102.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Antisense; 0 / DNA, Complementary; 0 / Lectins, C-Type; 0 / RNA, Messenger; 0 / pancreatitis-associated protein
  •  go-up   go-down


47. De La O JP, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB, Murtaugh LC: Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A; 2008 Dec 2;105(48):18907-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia.
  • Efforts to model pancreatic cancer in mice have focused on mimicking genetic changes found in the human disease, particularly the activating KRAS mutations that occur in pancreatic tumors and their putative precursors, pancreatic intraepithelial neoplasia (PanIN).
  • The basis for this selective response is unknown, and it is similarly unknown what cell types in the mature pancreas actually contribute to PanINs.
  • We hypothesize that Notch, which inhibits differentiation in the embryonic pancreas, contributes to PanIN formation by abrogating the normal differentiation program of tumor-initiating cells.
  • Furthermore, we find that Kras activation in mature acinar cells induces PanIN lesions identical to those seen upon ubiquitous Kras activation, and that Notch promotes both initiation and dysplastic progression of these acinar-derived PanINs, albeit short of invasive adenocarcinoma.
  • At the cellular level, Notch/Kras coactivation promotes rapid reprogramming of acinar cells to a duct-like phenotype, providing an explanation for how a characteristically ductal tumor can arise from nonductal acinar cells.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Development. 2002 May;129(10):2447-57 [11973276.001]
  • [Cites] Nat Med. 2002 Sep;8(9):979-86 [12185362.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14920-5 [14657333.001]
  • [Cites] Dev Dyn. 2004 Jan;229(1):176-200 [14699589.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Pancreas. 2004 Jan;28(1):58-64 [14707731.001]
  • [Cites] Methods Enzymol. 1987;152:219-27 [2443794.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):728-41 [15765408.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Genes Dev. 2005 Aug 15;19(16):1825-39 [16103211.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):544-55 [18242220.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • (PMID = 19028876.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21-CA123066; United States / NCI NIH HHS / CA / P30-CA042014; United States / NICHD NIH HHS / HD / 5T32-HD07491; United States / NCI NIH HHS / CA / CA123066-02; United States / NCI NIH HHS / CA / R21 CA123066; United States / NCI NIH HHS / CA / R21 CA123066-02; United States / NICHD NIH HHS / HD / T32 HD007491; United States / NCI NIH HHS / CA / P30 CA042014
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Notch; 094ZI81Y45 / Tamoxifen; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


48. Gürbüz Y, Yildiz K, Aydin O, Almaç A: Immunophenotypical profiles of salivary gland tumours: a new evidence for their histogenetic origin. Pathologica; 2006 Apr;98(2):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 30 cases of salivary gland tumours (18 pleomorphic adenomas, 8 Warthin's tumours, 2 basal cell adenomas, 2 acinic cell carcinomas) were included in our study.
  • SMA was not detected in Warthin's tumour (p < 0.0001).
  • CK14 was found in all tumours except acinic cell carcinomas (p < 0.0001).
  • CK10 immunoreactivity was observed in 5 Warthin's tumour.
  • Immunophenotypic profile of Warthin's tumour is suggestive of an embryological remnant origin.
  • [MeSH-major] Actins / analysis. Keratins / analysis. Neoplasm Proteins / analysis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenolymphoma / chemistry. Adenolymphoma / pathology. Adenoma / chemistry. Adenoma / pathology. Adenoma, Pleomorphic / chemistry. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / chemistry. Carcinoma, Acinar Cell / pathology. Humans. Immunophenotyping. Organ Specificity. Protein Isoforms / analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929788.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 68238-35-7 / Keratins
  •  go-up   go-down


49. Gaiser S, Ahler A, Gundling F, Kruse ML, Savkovic V, Selig L, Teich N, Tomasini R, Dagorn JC, Mössner J, Keim V, Bödeker H: Expression of mutated cationic trypsinogen reduces cellular viability in AR4-2J cells. Biochem Biophys Res Commun; 2005 Aug 26;334(2):721-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AR4-2J cells were transiently transfected with the different expression vectors and cell viability and intracellular caspase-3 activity were quantified.
  • In contrast to wild-type trypsinogen, expression of active trypsin and mutated trypsinogens reduced cell viability of AR4-2J cells.
  • Acinar cells might react to intracellular trypsin activity by triggering apoptosis.
  • [MeSH-major] Apoptosis. Cell Survival. Pancreatic Neoplasms / metabolism. Trypsin / metabolism. Trypsinogen / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Mutagenesis, Site-Directed. Rats. Recombinant Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036133.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 9002-08-8 / Trypsinogen; EC 3.4.21.4 / PRSS1 protein, human; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


50. Reske SN: [PET and PET-CT of malignant tumors of the exocrine pancreas]. Radiologe; 2009 Feb;49(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic acinar tumors are much rarer and originate from secretion-producing parenchymal cells of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoma, Acinar Cell / diagnostic imaging. Carcinoma, Pancreatic Ductal / diagnostic imaging. Image Processing, Computer-Assisted. Pancreatic Neoplasms / diagnostic imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis / diagnostic imaging. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Staging. Pancreas / diagnostic imaging. Pancreas / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2006 Nov-Dec;40(10 ):923-9 [17063113.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1437-44 [18703612.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Eur J Nucl Med. 1998 Mar;25(3):259-64 [9580859.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):250-5 [10025831.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1352 [15197505.001]
  • [Cites] J Gastroenterol. 2003;38(12 ):1189-93 [14714260.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9 [18043094.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):399-404 [15549297.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):475-6 [16012303.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Oct;26(10 ):888-92 [12434099.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1775-85 [18481063.001]
  • [Cites] Recent Results Cancer Res. 2008;177:15-26 [18084943.001]
  • [Cites] Nuklearmedizin. 2005;44 Suppl 1:S18-23 [16395974.001]
  • [Cites] Clin Nucl Med. 2002 Mar;27(3):197-201 [11852308.001]
  • [Cites] Scand J Surg. 2004;93(3):191-7 [15544073.001]
  • [Cites] Clin Positron Imaging. 1999 May;2(3):131-136 [14516536.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1408-13 [18703604.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):425-34 [16766262.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10 (10 ):1354-60 [17175454.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):50-5 [14767734.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):287-93 [10917540.001]
  • [Cites] Dig Surg. 2005;22(1-2):55-61; discussion 62 [15838173.001]
  • [Cites] Ann Nucl Med. 2001 Jun;15(3):217-24 [11545191.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Pancreas. 2005 Aug;31(2):192-4 [16025008.001]
  • [Cites] Pancreas. 2000 Mar;20(2):109-16 [10707924.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Pancreatology. 2005;5(6):553-61 [16113592.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):239-46 [15972430.001]
  • [Cites] J Nucl Med. 2008 Mar;49(3):480-508 [18287273.001]
  • [Cites] Pancreatology. 2005;5(2-3):266-72 [15855825.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19219476.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 43
  •  go-up   go-down


51. Abdul M, Mccray SD, Hoosein NM: Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer. Acta Oncol; 2008;47(8):1546-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have also examined the effect of several GABA agonists and antagonists on the in vitro proliferation of four human prostate cancer cell lines: LNCaP, MDA-PCA-2b, DU145 and PC3.
  • Also, low to moderate GABAar staining was observed in the acinar epithelium of 50 (33%) prostate cancer specimens.
  • A GABAa agonist isoguvacine, at doses between 5-50 microg/ml (31-310 microM), stimulated the proliferation of all four human prostate cancer cell lines, tested.
  • [MeSH-major] Prostatic Neoplasms / metabolism. Receptors, GABA-A / metabolism
  • [MeSH-minor] Bicuculline / pharmacology. Cell Proliferation / drug effects. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Dihydroergotoxine / pharmacology. GABA Agonists / pharmacology. GABA Antagonists / pharmacology. GABA-A Receptor Agonists. GABA-B Receptor Agonists. Humans. Isonicotinic Acids / pharmacology. Male. Picrotoxin / pharmacology. Prostate / metabolism. Prostate / pathology. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Receptors, GABA-B / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. PICROTOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607852.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR16461
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / GABA Antagonists; 0 / GABA-A Receptor Agonists; 0 / GABA-B Receptor Agonists; 0 / Isonicotinic Acids; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B; 11032-41-0 / Dihydroergotoxine; 124-87-8 / Picrotoxin; Y37615DVKC / Bicuculline; YTF580771Y / isoguvacine
  •  go-up   go-down


52. La Rosa S, Franzi F, Marchet S, Finzi G, Clerici M, Vigetti D, Chiaravalli AM, Sessa F, Capella C: The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch; 2009 Feb;454(2):133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.
  • Acinar cell carcinoma (ACC) is a rare pancreatic cancer which may be difficult to distinguish from other solid nonadenocarcinoma tumors.
  • The diagnosis depends on the demonstration of acinar differentiation, obtained with antibodies recognizing various pancreatic enzymes that, although specific, show different sensitivity.
  • The C-terminal portion of the BCL10 protein shows homology with carboxyl ester hydrolase (CEH), an enzyme produced by pancreatic acinar cells.
  • We investigated the usefulness of a C-terminal BCL10 monoclonal antibody in the diagnosis of ACCs.
  • We examined normal pancreases and different pancreatic tumors including ACCs, mixed acinar-endocrine carcinomas, ductal adenocarcinomas, mucinous, serous, solid pseudopapillary, and endocrine neoplasms.
  • In addition, various normal tissues and cases of pancreatic metaplasia of the gastroesophageal mucosa, cases of ectopic pancreas, gastrointestinal endocrine tumors, salivary and breast acinic cell carcinomas, gastric adenocarcinomas with and without acinar differentiation, and hepatocellular carcinomas were studied.
  • BCL10 immunoreactivity paralleled that of CEH and was restricted to acinar cells of normal and ectopic pancreas, of pancreatic metaplasia, and of ACCs.
  • We suggest using BCL10 antibody for diagnosing pancreatic tumors and whenever an acinar differentiation is suspected in gastrointestinal neoplastic and metaplastic lesions.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antibodies, Monoclonal / immunology. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 1998 Feb 1;329 ( Pt 3):675-9 [9445398.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):104-8 [10839610.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] FEBS Lett. 1991 Jan 28;278(2):190-4 [1991511.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):649-54 [16865281.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):248-54 [15517368.001]
  • [Cites] Differentiation. 1992 Sep;51(1):55-60 [1451962.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):869-73 [9224759.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Sep 15;155(2):950-5 [3421974.001]
  • [Cites] Eur J Biochem. 1990 Sep 11;192(2):543-50 [1698625.001]
  • [Cites] Biochim Biophys Acta. 1995 Oct 17;1272(2):69-72 [7548236.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Int J Pancreatol. 1989 Sep;5(2):123-34 [2689525.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S61-9 [17684764.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):1221-6 [2318975.001]
  • [Cites] Biochim Biophys Acta. 1978 Nov 10;527(1):142-9 [718955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12641-6 [9770539.001]
  • [Cites] APMIS. 1995 Jan;103(1):69-78 [7695893.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):363-70 [17325477.001]
  • [Cites] Genomics. 1993 Aug;17(2):416-22 [7691717.001]
  • (PMID = 19066953.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / BCL10 protein, human; 0 / Biomarkers, Tumor; EC 3.1.1.1 / Carboxylesterase
  •  go-up   go-down


53. Borka K: [Claudin expression in different pancreatic cancers and its significance in differential diagnostics]. Magy Onkol; 2009 Sep;53(3):273-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our studies was to compare the different CLDN expression patterns in normal pancreas cells, pancreatic endocrine tumors, adenocarcinomas, mucinous cystic tumors and acinar cell carcinomas.
  • ) In addition to the well-known CLDN-1 and -4 expression CLDN-2, -3 and -7 proteins were demonstrated in ductal cells, while CLDN-3 and -7 proteins showed expression in acinar cells.
  • 4.) This is a first review on childhood acinar cell carcinoma causing Cushing syndrome.
  • The adenocarcinomas and cystic mucinous tumors of exocrine origin denoted CLDN-1, -2, -4 and -7 positivity, whereas acinar cell carcinomas expressed only CLDN-1 and -2.
  • Considering the CLDN expression observed in normal pancreas cells, it can be established that CLDN-1, -2 and -4 proteins are definitely markers of ductal differentiation, CLDN-1 protein of acinar and CLDN-3 of endocrine differentiation. 2).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Claudins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793693.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


54. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR: Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell; 2010 Nov 16;18(5):499-509
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unexpectedly, tumor cells retain a functional Brca2 allele.
  • Three tumors from these patients displaying LOH were acinar carcinomas, which also developed only in mice with biallelic Brca2 inactivation.
  • We suggest a revised model for tumor suppression by BRCA2 with implications for the therapeutic strategy targeting BRCA2 mutant cancer cells.
  • [MeSH-major] BRCA2 Protein / genetics. Carcinoma, Pancreatic Ductal / genetics. Disease Models, Animal. Genes, BRCA2. Germ-Line Mutation. Heterozygote. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins p21(ras) / genetics
  • [MeSH-minor] Alleles. Animals. Cell Line, Tumor. Codon, Nonsense. Gene Silencing. Loss of Heterozygosity. Mice. Mice, 129 Strain. Mice, Inbred C57BL. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21056012.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359877; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / G9900064; United Kingdom / Medical Research Council / / G0600332; United Kingdom / Medical Research Council / / G0700651
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA2 Protein; 0 / Codon, Nonsense; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


55. Vacchi-Suzzi M, Bocciolini C, Bertarelli C, Dall'Olio D: Ki-67 proliferation rate as a prognostic marker in major salivary gland carcinomas. Ann Otol Rhinol Laryngol; 2010 Oct;119(10):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The study was performed to evaluate the prognostic relevance of cell proliferation associated with Ki-67/ Mib-1 immunostaining in malignant tumors of the major salivary glands.
  • METHODS: Cell proliferation was evaluated by Mib-1 antibody against Ki-67 antigen in 41 patients with cancer of the parotid or submandibular glands, including 14 acinic cell carcinomas, 12 ductal carcinomas, 7 mucoepidermoid carcinomas, 5 carcinomas ex pleomorphic adenoma, 1 adenoid cystic carcinoma, 1 undifferentiated carcinoma, and 1 polymorphous low-grade adenocarcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma, Acinar Cell / mortality. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Ductal / mortality. Carcinoma, Mucoepidermoid / mortality. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Parotid Neoplasms / mortality. Prognosis. Salivary Gland Neoplasms / mortality. Submandibular Gland Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049853.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


56. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM: Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia; 2008 Aug;10(8):782-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic evaluation revealed a chronic pancreatitis-like state characterized by acinar-to-ductal metaplasia and a well-vascularized fibroinflammatory stroma that develops by 3 months.
  • Increased proliferation, cellular atypia, and loss of normal cell/tissue organization are typical features in transgenic pancreata.
  • However, cell lines derived from spontaneous lesions are aggressively tumorigenic when injected into syngeneic or nude mice.
  • The progressive nature of the metaplastic/dysplastic changes observed in this model make it a valuable tool for examining the transition from chronic inflammation to neoplasia.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2007 Nov;9(11):979-86 [18030366.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Am J Clin Oncol. 2007 Oct;30(5):526-30 [17921715.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):139-46 [10657949.001]
  • [Cites] Genes Dev. 2000 Sep 1;14(17):2123-33 [10970876.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Jul;226(7):692-700 [11444106.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1403-4 [12045253.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):41-8 [15671526.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):575-84 [15681840.001]
  • [Cites] Cell Res. 2005 Jan;15(1):72-7 [15686632.001]
  • [Cites] Pancreas. 2005 Mar;30(2):148-57 [15714137.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):817-23 [15609315.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1808-13 [15753378.001]
  • [Cites] Gut. 2005 Apr;54(4):510-4 [15753536.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jun;55(6):559-64 [15726370.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1217-24 [15477758.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):436-9 [15982220.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1157-64 [15920540.001]
  • [Cites] Gut. 2005 Oct;54(10):1461-7 [15870229.001]
  • [Cites] JAMA. 2005 Dec 14;294(22):2872-8 [16352795.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1943-51 [16373709.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):583-90 [16034525.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2165-78 [16762637.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):437-45 [16820089.001]
  • [Cites] ChemMedChem. 2006 Jun;1(6):603-10 [16892400.001]
  • [Cites] JOP. 2006;7(5):465-72 [16998243.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1265-70 [16979953.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3240-7 [17172427.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1856-69 [17123526.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):2012-5 [17123529.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):50-9 [17200706.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • [Cites] Pancreatology. 2001;1(4):363-8 [12120215.001]
  • [Cites] Pancreas. 2002 Jul;25(1):26-30 [12131767.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):455-63 [12189387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12483-8 [12221288.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] Nat Rev Drug Discov. 2003 Nov;2(11):879-90 [14668809.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3127-38 [14681205.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Pancreas. 2004 Jan;28(1):58-64 [14707731.001]
  • [Cites] Pancreatology. 2003;3(6):487-96 [14673200.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1235-40 [14977820.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71 [15166955.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Pancreas. 2004 Oct;29(3):179-87 [15367883.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1121-35 [1693546.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1137-46 [2350785.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):559-68 [1372155.001]
  • [Cites] Differentiation. 1994 Nov;58(1):53-64 [7532601.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Microsc Res Tech. 1997 Jun 1-15;37(5-6):509-19 [9220428.001]
  • [Cites] Cancer J Sci Am. 1998 May-Jun;4(3):194-203 [9612602.001]
  • [Cites] Biotechniques. 1998 Jun;24(6):922-4, 926, 928 [9631181.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):317-24 [10069471.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):1223-9 [10233860.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:219-30 [10415867.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):194-202 [15644546.001]
  • [Cites] Annu Rev Physiol. 2007;69:249-69 [17059357.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Histol Histopathol. 2007 Jun;22(6):661-76 [17357096.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S113-31 [17486047.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] J Leukoc Biol. 2007 Aug;82(2):204-12 [17513693.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]
  • [Cites] Pancreas. 2007 Oct;35(3):212-7 [17895840.001]
  • (PMID = 18670639.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122815; United States / NCI NIH HHS / CA / R25 CA057730; United States / NIEHS NIH HHS / ES / T32 ES07247; United States / NCI NIH HHS / CA / R21 CA122815; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NIEHS NIH HHS / ES / ES07784; United States / NIEHS NIH HHS / ES / T32 ES007247; United States / NCI NIH HHS / CA / R25CA57730; United States / NCI NIH HHS / CA / CA105345; United States / NCI NIH HHS / CA / U01 CA105345
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pyrazoles; 0 / Sulfonamides; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2481568
  •  go-up   go-down


57. Furonaka O, Takeshima Y, Awaya H, Kushitani K, Kohno N, Inai K: Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int; 2005 Jun;55(6):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma.
  • The methylation status of the MGMT gene was investigated by methylation-specific polymerase chain reaction (PCR) and expression status was investigated by immunohistochemistry in 70 cases of pulmonary squamous cell carcinoma (pulmonary SqCC), including 23 cases of the central type and 47 cases of the peripheral type, and in 53 cases of the peripheral type of pulmonary adenocarcinoma (AC).
  • In AC with mixed subtypes showing MGMT methylation, the level of MGMT expression in the bronchioloalveolar carcinoma (BAC) area (non-invasive status) was significantly higher than that in the papillary or acinar AC area (invasive status; P = 0.0002).
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. DNA Methylation. Lung Neoplasms / pathology. O(6)-Methylguanine-DNA Methyltransferase / genetics
  • [MeSH-minor] DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943786.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


58. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, Choti MA, Wolfgang CL: Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg; 2008 Jun;12(6):1061-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature.
  • INTRODUCTION: Acinar cell carcinoma (ACC) is a rare, malignant neoplasm with a generally poor prognosis.
  • MATERIALS AND METHODS: The Johns Hopkins pathology prospective database was reviewed from 1988 to 2006 to identify patients with pancreatic neoplasms possessing features of acinar cell differentiation.
  • Median tumor size was 3.9 cm with 12 patients found to have stage IIB disease or worse.
  • CONCLUSION: Acinar cell carcinomas are rare, aggressive neoplasms that are difficult to diagnose and treat.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 1994 Jan;9(1):53-8 [8003821.001]
  • [Cites] Pancreas. 2001 Apr;22(3):326-9 [11291937.001]
  • [Cites] Can Med Assoc J. 1962 Nov 3;87:970-3 [14011794.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] Int Surg. 1984 Oct-Dec;69(4):361-4 [6084650.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] J Pathol. 1985 May;146(1):17-29 [2989468.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1568-71 [15619219.001]
  • [Cites] Gut. 1990 Aug;31(8):953-5 [2387523.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):85-93 [3812876.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):772-7 [11072247.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):397-402 [4005804.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Gastroenterology. 1965 Nov;49(5):555-9 [5853162.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Am J Surg. 2006 Feb;191(2):191-7 [16442944.001]
  • (PMID = 17957440.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Osumi D, Takahashi M, Miyoshi E, Yokoe S, Lee SH, Noda K, Nakamori S, Gu J, Ikeda Y, Kuroki Y, Sengoku K, Ishikawa M, Taniguchi N: Core fucosylation of E-cadherin enhances cell-cell adhesion in human colon carcinoma WiDr cells. Cancer Sci; 2009 May;100(5):888-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core fucosylation of E-cadherin enhances cell-cell adhesion in human colon carcinoma WiDr cells.
  • It was revealed that the low molecular weight population of E-cadherin was significantly increased in alpha1,6-fucosyltransferase-transfected WiDr cells in dense culture, which resulted in an enhancement in cell-cell adhesion.
  • In alpha1,6-fucosyltransferase knock down mouse pancreatic acinar cell carcinoma TGP49 cells, the expression of E-cadherin and E-cadherin dependent cell-cell adhesion was decreased.
  • The introduction of alpha1,6-fucosyltransferase into kidney epithelial cells from alpha1,6-fucosyltransferase(-/-) mice restored the expression of E-cadherin and E-cadherin-dependent cell-cell adhesion.
  • These results suggest a possible role of core fucosylation in the regulation of cell-cell adhesion in cancer.
  • [MeSH-major] Cadherins / metabolism. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Fucose / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Adhesion. Cell Line, Tumor. Female. Fucosyltransferases / deficiency. Fucosyltransferases / genetics. Fucosyltransferases / metabolism. Humans. Male

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302290.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 3713-31-3 / Fucose; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.68 / Glycoprotein 6-alpha-L-fucosyltransferase
  •  go-up   go-down


60. Iczkowski KA: Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med; 2006 Jun;130(6):835-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains.
  • CONCLUSIONS: Diagnosis begins by evaluating a focus of atypical single-cell layer lined acini according to the 3 minimal diagnostic criteria for cancer: an infiltrative pattern, nuclear enlargement and hyperchromasia, and prominent nucleoli.
  • Atypical small acinar proliferation suspicious for malignancy designates foci that have either qualitative or quantitative limitations in atypia precluding a definite cancer diagnosis.
  • Isolated high-grade prostatic intraepithelial neoplasia has a 3% to 14% incidence and predicts cancer on repeat biopsy in 23% of cases.
  • Immunostaining for a marker of benign prostate (cytoplasmic keratin 34betaE12 or nuclear p63) and a marker of cancer (alpha-methylacyl coA racemase, clone P504S) may or may not resolve atypical small acinar proliferation diagnoses.
  • Performance of 34betaE12 and P504S immunostains resolved 76% of atypical small acinar proliferation diagnoses per consensus of 3 urologic pathologists studied; a technical limitation is preservation of the focus in question on the levels used for immunostaining.
  • [MeSH-major] Immunohistochemistry / methods. Precancerous Conditions / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Cell Nucleus / pathology. Cell Proliferation. Humans. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740037.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


61. Abu-Yousif AO, Rizvi I, Evans CL, Celli JP, Hasan T: PuraMatrix encapsulation of cancer cells. J Vis Exp; 2009;(34)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increasing evidence suggests that culturing cancer cells in three dimensions more accurately recapitulates the complexity of tumor biology.
  • Many of these models utilize reconstituted basement membrane derived from animals which contain a variable amount of growth factors and cytokines that can influence the growth of these cell culture models.
  • Here, we describe in detail the preparation and use of PuraMatrix, a commercially available self assembling peptide gel that is devoid of animal-derived material and pathogens to encapsulate and propagate the ovarian cancer cell line, OVCAR-5.
  • Next, we demonstrate how to properly mix the PuraMatrix and cell suspension to encapsulate the cells in the hydrogel.
  • Upon the addition of cell culture media or injection into a physiological environment, the peptide component of PuraMatrix rapidly self assembles into a 3D hydrogel that exhibits a nanometer scale fibrous structure with an average pore size of 5-200 nm(1).
  • When encapsulated in PuraMatrix, OVCAR-5 cells assemble into three dimensional acinar structures that more closely resemble the morphology of micrometastatic nodules observed in the clinic than monolayer in vitro models.
  • [MeSH-major] Cytological Techniques / methods. Hydrogels / chemistry. Ovarian Neoplasms / pathology. Peptides / chemistry
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Microscopy, Confocal

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2006;1:e119 [17205123.001]
  • (PMID = 20019656.001).
  • [ISSN] 1940-087X
  • [Journal-full-title] Journal of visualized experiments : JoVE
  • [ISO-abbreviation] J Vis Exp
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydrogels; 0 / Peptides
  • [Other-IDs] NLM/ PMC3152243
  •  go-up   go-down


62. Cakir E, Demirag F, Aydin M, Unsal E: Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Diagn Cytopathol; 2009 Jan;37(1):4-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three features were selected to distinguish malignant mesothelioma from adenocarcinoma: giant atypical mesothelial cell (P = 0.0001), nuclear pleomorphism (P = 0.0001) and acinar structures (P = 0.0001), the latter two being characteristics of adenocarcinoma.
  • The variables selected to differentiate malignant mesothelioma from reactive mesothelial cells were: cell ball formation (P = 0.0001), cell in cell engulfment (P = 0.0001) and monolayer cell groups (P = 0.0001), the latter being a feature of benign mesothelial proliferation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Mesothelioma / diagnosis. Neoplasms, Mesothelial / diagnosis. Pleural Effusion, Malignant / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973123.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Oderda M, Gontero P: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: is repeat biopsy still necessary? BJU Int; 2009 Dec;104(11):1554-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: is repeat biopsy still necessary?
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817745.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Kawakami T, Nabeshima K, Hamasaki M, Iwasaki A, Shirakusa T, Iwasaki H: Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas. Virchows Arch; 2009 Jan;454(1):61-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SCI was defined as markedly resolved acinar-papillary tumor structures with single or small clusters of carcinoma cells invading stroma within fibrotic foci.
  • Carcinoma cells undergoing SCI demonstrated the same characteristic MUC-1 expression on the outer surface of cell clusters as those undergoing MPP.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Lymphatic Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1960 Sep;16:296-308 [13717558.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • [Cites] Virchows Arch. 2000 Oct;437(4):465-8 [11097376.001]
  • [Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]
  • [Cites] Histopathology. 2005 Nov;47(5):479-84 [16241995.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] Histopathology. 2005 Jun;46(6):677-84 [15910599.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):515-23 [10027409.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8089-93 [11719433.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):992-1001 [18516041.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • [Cites] Mod Pathol. 2007 May;20(5):514-21 [17334347.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):729-33 [17464318.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):809-15 [16784979.001]
  • [Cites] J Urol. 1999 Jun;161(6):1798-802 [10332438.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):836-41 [11557778.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1113-21 [11021815.001]
  • [Cites] Pathol Int. 2000 Jan;50(1):52-6 [10692178.001]
  • [Cites] Arch Pathol Lab Med. 2000 Sep;124(9):1347-8 [10975935.001]
  • [Cites] Cancer. 2004 Apr 25;102(2):81-6 [15098251.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2976-87 [16707592.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1045-50 [15154007.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):43-51 [8990140.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1224-32 [7977945.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):324-30 [18261622.001]
  • [Cites] Histopathology. 2004 Dec;45(6):580-6 [15569048.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4491-500 [10574699.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):319-26 [15104294.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):431-8 [8172319.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):857-66 [15198358.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):101-9 [12502932.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):638-47 [17431413.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1183-97 [10506935.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):419-24 [15982217.001]
  • (PMID = 19002492.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Capurso G, Crnogorac-Jurcevic T, Milione M, Panzuto F, Campanini N, Dowen SE, Di Florio A, Sette C, Bordi C, Lemoine NR, Delle Fave G: Peanut-like 1 (septin 5) gene expression in normal and neoplastic human endocrine pancreas. Neuroendocrinology; 2005;81(5):311-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal pancreatic tissue, purified islets, 11 PETs and two cell lines were used to evaluate the presence of PNUTL1 by RT-PCR and Western blot.
  • The expression of the PNUTL1 protein was also evaluated by immunohistochemistry on normal pancreas, additional 26 PETs, eight pancreatic adenocarcinomas, one mixed endocrine-exocrine pancreatic neoplasm, a specimen of solid papillary pseudomucinous tumor, an adult islet cell hyperplasia and a case of neonatal nesidioblastosis.
  • In addition, a tissue array (LandMark High Density Cancer Tissue MicroArray) comprising 280 various tumor and matched normal specimens was utilized.
  • In the normal pancreas PNUTL1 expression is almost exclusively confined to the islet cells, weak expression was occasionally seen in some acinar cells, while immunoreactivity was completely absent in the ductal epithelia.
  • Weak immunoreactivity was also noted in a proportion of exocrine neoplasms.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Gene Expression / physiology. Gene Expression Regulation, Neoplastic / physiology. Islets of Langerhans / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16179808.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / RNA, Messenger; EC 3.6.1.- / SEPT5 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


66. Antonello D, Gobbo S, Corbo V, Sipos B, Lemoine NR, Scarpa A: Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma. Pancreatology; 2009;9(1-2):25-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Although ductal adenocarcinoma is the most common and well known pancreatic tumor type, other distinct epithelial neoplasms affecting the pancreas that show different symptoms, biological behaviors and outcomes are becoming more frequently recognized and documented.
  • Pancreatic epithelial tumors may be separated into ductal and nonductal neoplasms.
  • The former group includes pancreatic ductal adenocarcinoma, intraductal papillary-mucinous tumor, mucinous cystic tumor and serous cystic tumor.
  • The latter group includes pancreatic endocrine tumor, pancreatic acinar cell carcinoma, pancreatoblastoma and solid-pseudopapillary tumor.
  • The aim of this review is to summarize recently acquired knowledge regarding the molecular characterization of these uncommon pancreatic epithelial neoplasms.
  • RECENT FINDINGS: Molecular studies of uncommon pancreatic epithelial tumors suggest that the different morphological entities are associated with distinct molecular profiles, highlighting the involvement of different molecular pathways leading to the development of each subtype of pancreatic neoplasm.
  • [MeSH-major] Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / pathology. Cystadenoma, Mucinous / genetics. Cystadenoma, Mucinous / pathology. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077452.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 120
  •  go-up   go-down


67. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI: Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol; 2008 Mar;32(3):461-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Needle biopsy cases ranged from Gleason patterns 3 to 5 with tumor identified on one or more cores, ranging from a minute focus to 80% of the core.
  • In all 8 radical prostatectomies p63 positive cancer was present, with in 2/8 cases both p63 positive cancer and usual p63 negative acinar prostate cancer.
  • Rarely, prostate cancer can aberrantly express diffuse p63 staining in a nonbasal cell distribution leading to the erroneous diagnosis of atrophy or atypical basal cell proliferation.
  • [MeSH-major] Adenocarcinoma / chemistry. Biopsy, Needle. Membrane Proteins / analysis. Prostatectomy. Prostatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300803.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


68. Shah S, Mortele KJ: Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, and magnetic resonance imaging features. Semin Ultrasound CT MR; 2007 Oct;28(5):357-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, and magnetic resonance imaging features.
  • Various uncommon solid pancreatic neoplasms, including exocrine and endocrine epithelial tumors, mesenchymal tumors, and metastases, are reviewed, with emphasis on key differential points, including morphologic features and patterns of contrast enhancement.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / pathology. Contrast Media. Diagnosis, Differential. Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / pathology. Humans. Lymphoma / diagnosis. Lymphoma / pathology. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Complex and Mixed / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970552.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 41
  •  go-up   go-down


69. Kebir FZ, Lahmar A, Arfa N, Manai S, El Ouaer MA, Bouraoui S, Gouttalier C, Mezabi-Regaya S: Acinar cell carcinoma of the pancreas in a young patient with chronic pancreatitis. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):103-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas in a young patient with chronic pancreatitis.
  • BACKGROUND: Acinar cell carcinoma (ACC) is a rare malignancy of the pancreas arising from acinar cells.
  • Unlike ductal adenocarcinoma, this tumor rarely presents with pancreatitis.
  • CONCLUSIONS: The clinical presentation of ACC of the pancreas is not specific and the tumor can be under-diagnosed when associated with chronic pancreatitis.
  • Data regarding course, treatment, and prognosis of this tumor are generally lacking.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / complications

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133240.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Bowne WB, Sookraj KA, Vishnevetsky M, Adler V, Sarafraz-Yazdi E, Lou S, Koenke J, Shteyler V, Ikram K, Harding M, Bluth MH, Ng M, Brandt-Rauf PW, Hannan R, Bradu S, Zenilman ME, Michl J, Pincus MR: The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol; 2008 Dec;15(12):3588-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.
  • These peptides induce tumor cell necrosis of cancer cells, but not normal cells.
  • Since there is evidence that penetratin is required for tumor cell necrosis, we tested "naked" p53 peptide without penetratin by transfecting a plasmid that encodes p53 aa17-26 segment of PNC-28 into MiaPaCa-2 and an untransformed rat pancreatic acinar cell line, BMRPA1.
  • RESULTS: Treatment with PNC-28 does not result in the elevation of proapoptotic proteins found in p53-induced apoptosis, but elicits rapid release of LDH, indicative of tumor cell necrosis.
  • Cancer cell death by apoptosis was observed in the absence of penetratin.
  • [MeSH-major] Apoptosis / drug effects. Carrier Proteins / pharmacology. Pancreatic Neoplasms / pathology. Peptide Fragments / pharmacology. Tumor Suppressor Protein p53 / pharmacology
  • [MeSH-minor] Caspases / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Humans. L-Lactate Dehydrogenase / metabolism. Necrosis. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931881.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA42500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / PNC-28; 0 / Peptide Fragments; 0 / Tumor Suppressor Protein p53; 0 / penetratin; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.22.- / Caspases; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


71. Stelow EB, Bardales RH, Shami VM, Woon C, Presley A, Mallery S, Lai R, Stanley MW: Cytology of pancreatic acinar cell carcinoma. Diagn Cytopathol; 2006 May;34(5):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of pancreatic acinar cell carcinoma.
  • Acinar cell carcinoma (ACC) of the pancreas is extremely uncommon and its cytologic features have rarely been described.
  • Original cytologic diagnoses included "acinar cell carcinoma," "pancreatic endocrine tumor," "favor neuroendocrine tumor, low-grade" and "non-diagnostic specimen."
  • The cytologic features included small to moderate-sized loose groups with numerous single cells, prominent acinar formation, little anisonucleosis and prominent nucleoli.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Female. Humans. Keratins / analysis. Liver Neoplasms / chemistry. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged. Pancreas / chemistry. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604543.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


72. Suh SI, Seol HY, Kim TK, Lee NJ, Kim JH, Kim KA, Woo JS, Lee JH: Acinic cell carcinoma of the head and neck: radiologic-pathologic correlation. J Comput Assist Tomogr; 2005 Jan-Feb;29(1):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the head and neck: radiologic-pathologic correlation.
  • OBJECTIVE: To describe and correlate the imaging and pathologic findings of acinic cell carcinoma (ACC) in the head and neck.
  • A parapharyngeal lesion was cystic mass with mural nodule, and a submandibular and a palate tumor were cystic lesions on CT.
  • [MeSH-major] Carcinoma, Acinar Cell / radiography. Head and Neck Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Child, Preschool. Diagnosis, Differential. Female. Hemorrhage / pathology. Hemorrhage / radiography. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Necrosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Palatal Neoplasms / pathology. Palatal Neoplasms / radiography. Parotid Neoplasms / pathology. Parotid Neoplasms / radiography. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiography. Retrospective Studies. Submandibular Gland Neoplasms / pathology. Submandibular Gland Neoplasms / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665697.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Skálová A, Sima R, Vanecek T, Muller S, Korabecna M, Nemcova J, Elmberger G, Leivo I, Passador-Santos F, Walter J, Rousarova M, Jedlickova K, Curik R, Geierova M, Michal M: Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol; 2009 Aug;33(8):1137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes.
  • High-grade transformation of acinic cell carcinoma (AciCC) (previously referred to as dedifferentiation) is a rare phenomenon characterized by histologic progression of low-grade AciCC to high-grade adenocarcinoma or undifferentiated carcinoma.
  • We report 9 new cases with immunohistochemical analysis and examination of HER-2/neu and p53 genes to further define the profile of this tumor.
  • Six of 9 patients (66%) died from tumor dissemination, all with a median overall survival of 4.3 years (range: 1 to 9 y).
  • [MeSH-major] Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / pathology. Genes, erbB-2. Genes, p53. Parotid Neoplasms / genetics. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic / genetics. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


74. Karafin MS, Cummings CT, Fu B, Iacobuzio-Donahue CA: The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol; 2009 Aug 30;3(1):47-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, GATA4 mRNA expression is upregulated in pancreatic cancer cell lines and tissues.
  • Immunolabeling for GATA4 indicated robust nuclear expression in developing acini in fetal pancreatic tissues, consistent with the role of GATA4 in embryologic development, and in mature pancreatic acinar epithelium.
  • Immunolabeling for GATA4 was also noted within normal duct epithelial cells, although it was always lesser in intensity than for acinar cell nuclei in the same section.
  • These findings support previous studies implicating GATA4 in pancreatic cancer and offer new avenues for investigation into this aggressive tumor type.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2003 Mar 1;255(1):12-29 [12618131.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3990-7 [19509152.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8429-39 [14612389.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4993-5005 [8262042.001]
  • [Cites] Lab Invest. 1995 Apr;72(4):395-404 [7723277.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7917-24 [15585625.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21022-8 [15793308.001]
  • [Cites] Development. 2005 Sep;132(17):4005-14 [16079152.001]
  • [Cites] Dev Dyn. 2005 Oct;234(2):355-62 [16127717.001]
  • [Cites] Dev Growth Differ. 2005 Dec;47(9):591-600 [16316404.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):281-8 [16337738.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5446-61 [16607277.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3925-31 [11061558.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38949-52 [11042222.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):784-9 [11937486.001]
  • [Cites] Curr Opin Genet Dev. 2002 Aug;12(4):416-22 [12100886.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2078-83 [16823849.001]
  • [Cites] Dev Biol. 2006 Oct 15;298(2):415-29 [16887115.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Apr;36(4):391-7 [17142311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):8053-8 [17463088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14994-9 [17848526.001]
  • [Cites] Development. 2007 Dec;134(24):4459-68 [18003741.001]
  • [Cites] Cancer Biol Ther. 2007 Oct;6(10):1546-52 [17912029.001]
  • [Cites] BMC Mol Biol. 2008;9:44 [18445271.001]
  • [Cites] Development. 2008 Nov;135(22):3731-43 [18927154.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1593-601 [18769116.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8515-24 [9079680.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Mol Endocrinol. 2009 Oct;43(4):157-69 [19491195.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • (PMID = 19918328.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA106610; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2776266
  • [Keywords] NOTNLM ; Pancreatic cancer / development / embryology / transcription factor
  •  go-up   go-down


75. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM: DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med; 2009 May 26;6(5):e1000068
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
  • Here we report the discovery of DEAR1 (ductal epithelium-associated RING Chromosome 1), a novel gene encoding a member of the TRIM (tripartite motif) subfamily of RING finger proteins, and provide evidence for its role as a dominant regulator of acinar morphogenesis in the mammary gland and as an independent predictor of local recurrence-free survival in early-onset breast cancer.
  • DEAR1 missense mutations and homozygous deletion (HD) were discovered in breast cancer cell lines and tumor samples.
  • Introduction of the DEAR1 wild type and not the missense mutant alleles to complement a mutation in a breast cancer cell line, derived from a 36-year-old female with invasive breast cancer, initiated acinar morphogenesis in three-dimensional (3D) basement membrane culture and restored tissue architecture reminiscent of normal acinar structures in the mammary gland in vivo.
  • Stable knockdown of DEAR1 in immortalized human mammary epithelial cells (HMECs) recapitulated the growth in 3D culture of breast cancer cell lines containing mutated DEAR1, in that shDEAR1 clones demonstrated disruption of tissue architecture, loss of apical basal polarity, diffuse apoptosis, and failure of lumen formation.
  • CONCLUSIONS: Our data provide compelling evidence for the genetic alteration and loss of expression of DEAR1 in breast cancer, for the functional role of DEAR1 in the dominant regulation of acinar morphogenesis in 3D culture, and for the potential utility of an immunohistochemical assay for DEAR1 expression as an independent prognostic marker for stratification of early-onset disease.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jun 20;417(6891):871-5 [12075357.001]
  • [Cites] Cell. 2008 Nov 28;135(5):865-78 [19041750.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):521-6 [12522268.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] J Cell Biol. 2004 Feb 16;164(4):603-12 [14769856.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2358-62 [14630830.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1264-74 [15316900.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):985-90 [3657865.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7351-7 [1977518.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):48-58 [2487147.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):997-1003 [2033434.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):327-31 [1677695.001]
  • [Cites] Dev Biol. 1991 Nov;148(1):107-16 [1936552.001]
  • [Cites] EMBO J. 1992 Feb;11(2):629-42 [1311253.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1468-74 [10188892.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2182-9 [10232606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] Trends Biochem Sci. 1992 Sep;17(9):344-5 [1412709.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5305-10 [1437549.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10877-81 [1438292.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Nov;5(4):311-20 [1283319.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Ann N Y Acad Sci. 1993 Jun 11;684:174-92 [8317827.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3383-7 [8159756.001]
  • [Cites] N Engl J Med. 1994 Jun 2;330(22):1580-8 [8177249.001]
  • [Cites] Semin Cancer Biol. 1994 Apr;5(2):157-65 [8061331.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] EMBO J. 1995 May 1;14(9):2020-33 [7744009.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):138-44 [7622286.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):19-27 [7666458.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Cell. 1997 Aug 22;90(4):797-807 [9288758.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):25-31 [9288094.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):285-91 [9354791.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3533-7 [9721855.001]
  • [Cites] Cancer J Sci Am. 1998 Sep-Oct;4(5):302-7 [9815294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 [9843973.001]
  • [Cites] Biochem Cell Biol. 1998;76(2-3):351-8 [9923704.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):298-301 [10888877.001]
  • [Cites] Hum Mol Genet. 2000 Oct 12;9(17):2553-62 [11030761.001]
  • [Cites] EMBO J. 2001 May 1;20(9):2140-51 [11331580.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Lancet. 2002 Apr 27;359(9316):1471-7 [11988246.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):354-61 [10398429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9176-81 [15967981.001]
  • [Cites] Cell. 2006 Aug 11;126(3):489-502 [16901783.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1235-45 [17060907.001]
  • [Cites] Cell. 2007 Feb 9;128(3):459-75 [17289567.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 31;360(3):531-8 [17624313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):35-42 [17855007.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • (PMID = 19536326.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / F32 CA090036-01A1; United States / NCI NIH HHS / CA / F32 CA090036-02; United States / NCI NIH HHS / CA / CA090036-01A1; United States / NCI NIH HHS / CA / T32CA09299; United States / NCI NIH HHS / CA / CA090036-02; United States / NCI NIH HHS / CA / T32 CA009299; United States / NCI NIH HHS / CA / F32 CA090036
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Proteins; EC 6.3.2.19 / TRIM62 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2673042
  •  go-up   go-down


76. Guzzo M, Ferrari A, Marcon I, Collini P, Gandola L, Pizzi N, Casanova M, Mattavelli F, Scaramellini G: Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan. Pediatr Blood Cancer; 2006 Nov;47(6):806-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan.
  • These results are presented in conjunction with a literature review of salivary tumors with a view to providing an up-to-date overview of the clinical course, prognosis, and treatment options for this rare tumor.
  • PROCEDURE: Fifty-two cases of epithelial salivary tumors were reviewed and the clinical-pathological information concerning tumor characteristics, therapy, and follow-up were collected.
  • RESULTS: The major salivary glands were the main site of tumor occurrence (79% of cases arose in parotid glands); 37 patients had benign tumors (pleomorphic adenoma), 15 had malignant tumors (12 mucoepidermoid carcinoma, 9 low grade).
  • When tumor enucleation was performed, recurrences occurred in 50% of benign neoplasms.
  • At the time of the report, all patients with benign tumors were alive, 35(95%) without evidence of disease; only one patient with malignant tumor died of disease.
  • CONCLUSIONS: Epithelial salivary glands tumor in children had different characteristics compared with their adult counterpart with respect to the frequency of histotypes and site of occurrence, but their prognosis seems to be similar.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Carcinoma, Acinar Cell / surgery. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Neoplasm Recurrence, Local / surgery. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16425245.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Pavlakis K, Stravodimos K, Kapetanakis T, Gregorakis A, Athanassiadou S, Tzaida O, Constantinides C: Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens. Int Urol Nephrol; 2010 Jun;42(2):325-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lack of basal cell staining in more than three glands for 34betaE12 and p63 occurred in 41 (27.5%) and 9 (6%) respective cases from the General Hospital pool.
  • With the aid of P504S positivity, a case of prostate cancer as well as another of atypical small acinar proliferation was discovered.
  • [MeSH-major] Keratins / analysis. Membrane Proteins / analysis. Prostate / chemistry. Prostate / pathology. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / pathology. Racemases and Epimerases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2006 May;97(5):1109-15 [16643500.001]
  • [Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):248-53 [17210521.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Am J Pathol. 1984 Feb;114(2):309-21 [6320650.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):220-5 [14983935.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1764-7 [11100054.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):75-8 [15163024.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):579-87 [15832080.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] Mod Pathol. 1999 May;12(5):472-8 [10349984.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):701-5 [15166661.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1239-46 [9777986.001]
  • (PMID = 19655267.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


78. Cohn ML, Elliott DD, El-Naggar AK: Metastatic acinic cell carcinoma in a neurofibroma mistaken for carcinosarcoma. Head Neck; 2005 Jan;27(1):76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinic cell carcinoma in a neurofibroma mistaken for carcinosarcoma.
  • BACKGROUND: Tumor-to-tumor metastasis is a rare, but well-recognized, entity most commonly involving metastatic carcinoma to a mesenchymal neoplasm.
  • We report a case of acinic cell carcinoma of the parotid gland metastatic to a neurofibroma.
  • METHODS AND RESULTS: A 55-year-old man with a history of a high-grade acinic cell carcinoma of the parotid was seen with a mass at the surgical site and metastatic foci in the scalp 10 months postoperatively.
  • The resection specimen revealed a spindle cell lesion with metastatic foci of high-grade adenocarcinoma, initially diagnosed as a carcinosarcoma.
  • The bland morphology and S-100-positive expression of the spindle cell lesion confirmed the diagnosis of neurofibroma.
  • The high-grade features of the carcinomatous foci and their similarity to the primary tumor confirmed the presence of a tumor-to-tumor metastasis.
  • CONCLUSION: To our knowledge, this is the first reported case of acinic cell carcinoma metastatic to a neurofibroma, an important entity in the differential diagnosis of biphasic tumors of the head and neck.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Neurofibroma / pathology. Parotid Neoplasms / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Ear, External / pathology. Humans. Male. Middle Aged. Soft Tissue Neoplasms / pathology. Temporal Bone / pathology


79. Schwentner I, Obrist P, Thumfart W, Sprinzl G: Distant metastasis of parotid gland tumors. Acta Otolaryngol; 2006 Apr;126(4):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nevertheless all patients who have a histologically confirmed malignant salivary gland tumor should have lifelong follow-up.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Ileal Neoplasms / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / secondary. Fatal Outcome. Humans. Immunohistochemistry. Incidence. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Parotid Gland / pathology. Parotid Gland / surgery. Salivary Ducts / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608783.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 32
  •  go-up   go-down


80. Pickup M, Van der Kwast TH: My approach to intraductal lesions of the prostate gland. J Clin Pathol; 2007 Aug;60(8):856-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By current convention, all high-grade intra-acinar and intraductal neoplastic lesions of prostatic origin fall under the diagnostic umbrella term: prostatic intraepithelial neoplasm (PIN).
  • Illustrating this fact, the well-described ductal subtype of prostatic adenocarcinoma is frequently associated with conventional-type acinar adenocarcinoma, and has a tendency to propagate within adjacent intact prostatic ducts.
  • As yet, however, many of these lesions have escaped the establishment of reliable morphologic criteria or immunohistochemical differentiation for diagnosis.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor. Carcinoma, Acinar Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Male. Neoplasm Invasiveness. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):19-43 [11144897.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] Semin Urol Oncol. 1999 Nov;17(4):187-98 [10632120.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):655-65 [11041054.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):3-10 [11144902.001]
  • [Cites] Prostate. 1988;12(1):39-46 [2450341.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):619-33 [2456702.001]
  • [Cites] Semin Diagn Pathol. 1988 Aug;5(3):301-11 [2845546.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):524-34 [11505396.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):341-4 [12400988.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Prog Urol. 2004 Jun;14(3):411-3 [15373189.001]
  • [Cites] Am J Clin Pathol. 1967 Apr;47(4):497-504 [4164333.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] J Urol. 1971 Dec;106(6):892-902 [5116310.001]
  • [Cites] Cancer. 1976 May;37(5):2255-62 [130969.001]
  • [Cites] J Urol. 1979 Mar;121(3):303-5 [219263.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1566-73 [4027893.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Prostate. 1987;10(2):123-31 [2436204.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):30-6 [7802135.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):330-6 [8674012.001]
  • [Cites] Prostate. 1996 Sep;29(3):137-45 [8827081.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Hum Pathol. 1997 Feb;28(2):143-8 [9023393.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):703-7 [9477103.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):413-8 [9523662.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):46-9 [9662249.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):145-52 [9921986.001]
  • [Cites] Eur Urol. 1999;35(5-6):479-83 [10325509.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):781-5 [10403300.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1503-7 [10667430.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1039-46 [10935644.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Virchows Arch. 2005 May;446(5):511-6 [15821929.001]
  • [Cites] Hum Pathol. 2005 May;36(5):531-5 [15948120.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):646-54 [16021571.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):826-32 [17032499.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • (PMID = 17237185.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 71
  • [Other-IDs] NLM/ PMC1994484
  •  go-up   go-down


81. van der Schroeff MP, Terhaard CH, Wieringa MH, Datema FR, Baatenburg de Jong RJ: Cytology and histology have limited added value in prognostic models for salivary gland carcinomas. Oral Oncol; 2010 Sep;46(9):662-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In multivariate analyses sex, tumor size, N- and M-staging, localization, comorbidity, skin involvement and pain were independent predictors of survival.
  • Histology was an independent prognostic factor, mainly because acinic cell carcinoma acted differently from the other histological subtypes.
  • The added prognostic value of cytology and/or histology factors in salivary carcinoma is limited, largely due to the combined prognostic value of other prognostic factors such as tumor size, N- and M-classification and comorbidity.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20637682.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


82. Takechi Y, Shinozaki T, Fukuda T, Asami K, Yanagawa T, Takagishi K: Multiple subcutaneous inflammation, osteolysis, and polyarthritis. Skeletal Radiol; 2010 Jun;39(6):581-2, 601-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arthritis / diagnosis. Carcinoma, Acinar Cell / diagnosis. Dermatitis / diagnosis. Fat Necrosis / diagnosis. Osteolysis / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20174794.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Kawakami H, Kuwatani M, Onodera M, Hirano S, Kondo S, Nakanishi Y, Itoh T, Asaka M: Primary acinar cell carcinoma of the ampulla of Vater. J Gastroenterol; 2007 Aug;42(8):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the ampulla of Vater.
  • Acinar cell carcinoma of the pancreatobiliary system is a relatively rare malignant neoplasm arising usually in the pancreatic parenchyma.
  • The patient underwent a curative surgical operation, and histopathological examination revealed that the tumor was confined to the ampulla of Vater with no continuity to the pancreatic parenchyma.
  • The tumor cells showed acinar or tubular arrangement with eosinophilic to basophilic granular cytoplasm, findings identical to those of acinar cell carcinoma of the pancreas.
  • Immunohistochemically, the tumor cells were positive for lipase.
  • From these findings, we concluded that the tumor was primary acinar cell carcinoma arising in the ampulla of Vater, probably originating from heterotopic pancreatic tissue.
  • This is the first reported case of primary acinar cell carcinoma in the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Acinar Cell / diagnosis. Common Bile Duct Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] Dig Surg. 2005;22(5):377-9 [16432300.001]
  • [Cites] Arch Pathol Lab Med. 1994 May;118(5):568-71 [8192567.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):121-3 [11154509.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):101-7 [9020300.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):449-51 [12055683.001]
  • (PMID = 17701134.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


84. Liu YL, Matsuzaki T, Nakazawa T, Murata S, Nakamura N, Kondo T, Iwashina M, Mochizuki K, Yamane T, Takata K, Katoh R: Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues. Hum Pathol; 2007 Jan;38(1):171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the expression of AQP3 in normal and neoplastic lung tissues, we studied a series of 149 lung carcinoma tissues and 2 cell lines by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction.
  • Squamous cell carcinoma and large cell carcinoma had rather low positive ratios (35.8% and 13.4%, respectively).
  • No AQP3 expression was demonstrated in small cell carcinoma, pleomorphic carcinoma, or metastatic colon adenocarcinoma.
  • Papillary subtype also showed a higher positive ratio of AQP3 compared with that in acinar and solid with mucin subtypes.
  • In addition, AQP3 expression was related to tumor differentiation and clinical stage in adenocarcinomas.
  • Western blotting and reverse transcriptase-polymerase chain reaction analyses confirmed the expression of AQP3 protein and messenger RNA in cell lines and tissues of lung adenocarcinoma.
  • [MeSH-major] Aquaporin 3 / genetics. Lung / metabolism. Lung Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056099.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 158801-98-0 / Aquaporin 3
  •  go-up   go-down


85. Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R: Matrix metalloproteinase (MMP)-7 in salivary gland cancer. Acta Oncol; 2010;49(1):85-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By age-adjusted analysis lower staining intensity was associated with worse overall survival of patients with acinic cell carcinoma (p = 0.047, HR 6.5, 95% Cl 1.0-41.7) and in mucoepidermoid carcinoma (p = 0.010, HR 9.3, 95% CI 1.7-50.0).
  • Low staining intensity was also associated with worse disease-specific survival of patients with acinic cell carcinoma (0-1 vs. 2-3; p = 0.047, HR 13.7, 1.0-200.0).
  • CONCLUSIONS: MMP-7 is associated with the prognosis of patients with acinic cell and mucoepidermoid carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Mucoepidermoid / metabolism. Matrix Metalloproteinase 7 / biosynthesis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929564.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


86. Wang Y, Xie SL, Wang CF, Liu SM, Shan Y, Zhao DB, Liu Q, Luo W, Zhao P: [Clinical and pathological analysis of 114 cases with non-ductal pancreatic adenocarcinoma occupying lesions]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1089-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (4) pancreaticoduodenectomy was performed in 26 patients, distal pancreatectomy in 53, tumor enucleation in 15, segmental pancreatectomy in 9, partial resection in 3, duodenum-preserving pancreatic head resection in 1 and palliative surgery (either cholecystojejunostomy anastomosis or gastrojejunostomy) in 7;.
  • (5) pathologic analysis revealed 35 solid pseudopapillary neoplasm of pancreas, 28 pancreatic endocrine tumors, 18 focal chronic pancreatitis, 11 serous cystic neoplasms, 9 mucinous cystic neoplasms, 4 pancreatic cysts, 3 acinar cell carcinomas, 2 pancreatic cavernous hemangiomas, 1 sarcoma of pancreas, 1 sarcomatoid carcinoma of pancreas, 1 pancreatic schwannoma and 1 pancreatic neuroblastoma.
  • CONCLUSION: The non-ductal pancreatic adenocarcinoma-occupying lesions have no specific clinical presentation or serum tumor marker.
  • [MeSH-major] Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. CA-19-9 Antigen / metabolism. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646423.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


87. Ballas KD, Rafailidis SF, Demertzidis C, Alatsakis MB, Pantzaki A, Sakadamis AK: Mixed exocrine-endocrine tumor of the pancreas. JOP; 2005 Sep;6(5):449-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed exocrine-endocrine tumor of the pancreas.
  • CONTEXT: Neoplasms of the pancreas usually show ductal, acinar or endocrine differentiation.
  • We herein describe a case of a mixed ductal-endocrine tumor.
  • Upper gastrointestinal endoscopy revealed gastric fundus varices and CT scan demonstrated an inhomogeneous tumor located in the tail of the pancreas infiltrating the spleen and the splenic vein.
  • Pathological examination revealed a mixed ductal-endocrine tumor.
  • [MeSH-major] Carcinoma, Islet Cell / pathology. Carcinoma, Pancreatic Ductal / pathology. Mixed Tumor, Malignant / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186667.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Gastrins; 51110-01-1 / Somatostatin; 9007-92-5 / Glucagon; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


88. Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A: Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch; 2005 Mar;446(3):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
  • Basal cell tumours of the prostatic gland are rare, and the classification is difficult.
  • In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma.
  • However, there were no definite criteria for a malignant behaviour of the basal cell tumour.
  • Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour.
  • The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):799-801 [8343043.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] Eur Urol. 1999;36(1):21-30 [10364651.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):668-72 [14999772.001]
  • [Cites] Histopathology. 1992 Feb;20(2):151-5 [1559669.001]
  • [Cites] Pathol Res Pract. 1990 Feb;186(1):28-36 [2179908.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):787-91 [14756145.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1523-9 [14657711.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):43-51 [12107088.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1225-33 [2400973.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1447-50 [9865831.001]
  • (PMID = 15726402.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Jorgenson TC, Williams BR, Wendland A, Bilger A, Sandgren EP, Drinkwater NR: Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer. Cancer Res; 2010 Nov 1;70(21):8398-406
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this model, KRAS oncogene expression is driven by an elastase promoter in acinar cells of the pancreas on an FVB/NTac (FVB) background [FVB-Tg(Ela-KRAS(G12D))] with the transgene carried on the Y chromosome.
  • Markers on chromosome 2 segregated with high tumor multiplicity in all three strains; these loci were designated Prsq1-3 (pancreatic ras susceptibility quantitative trait loci 1-3; combined F2 and N2 LOD(W), 6.0, 4.1, and 2.7, respectively).
  • A marker on chromosome 12 segregated with tumor multiplicity in a BALB × FVB-Tg(Ela-KRAS(G12D)) cross and was designated Prsq6 (LOD(W), ∼2.5).
  • Our findings provide evidence that regions of chromosomes 2, 4, and 12 influence the development and progression of pancreatic neoplasms initiated by an oncogenic allele of KRAS in mice.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Pancreas. 2008 Oct;37(3):e39-44 [18815537.001]
  • [Cites] Cancer Cell. 2009 Nov 6;16(5):379-89 [19878870.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):144-52 [10655059.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3182-92 [10918573.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):310-8 [11113205.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87 [11960696.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5960-6 [12185599.001]
  • [Cites] Genome Res. 2003 Mar;13(3):485-91 [12618379.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] J Mol Biol. 2004 Jul 23;340(5):921-32 [15236956.001]
  • [Cites] Genetics. 2004 Jun;167(2):859-66 [15238534.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Genetics. 1994 Nov;138(3):963-71 [7851788.001]
  • [Cites] Genetics. 1995 Mar;139(3):1421-8 [7768449.001]
  • [Cites] Nature. 1996 Mar 14;380(6570):149-52 [8600386.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):843-6 [15731001.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):511-7 [15942717.001]
  • [Cites] BMC Cancer. 2005;5:98 [16086840.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9637-42 [16266982.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 [16585505.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):721-30 [16688744.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):111-25 [18272835.001]
  • [Cites] Arch Pathol Lab Med. 2009 Mar;133(3):375-81 [19260743.001]
  • (PMID = 20959479.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076361; United States / NCI NIH HHS / CA / P01 CA022484; United States / NCI NIH HHS / CA / P01CA022484; United States / NCI NIH HHS / CA / R01CA076361; United States / NCI NIH HHS / CA / T32 CA009135
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS305961; NLM/ PMC3141286
  •  go-up   go-down


90. Spencer ML, Neto AG, Fuller GN, Luna MA: Intracranial extension of acinic cell carcinoma of the parotid gland. Arch Pathol Lab Med; 2005 Jun;129(6):780-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial extension of acinic cell carcinoma of the parotid gland.
  • We report the case of a 47-year-old woman who experienced multiple recurrences of acinic cell carcinoma, lung metastasis, and intracranial extension of the tumor during a 32-year period.
  • In this report, the clinical, microscopic, histochemical, and electron microscopy features of this acinic cell carcinoma are described, and a review of published information about this neoplasm is presented.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Neoplasm Recurrence, Local / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Cytoplasm / ultrastructure. Cytoplasmic Granules / chemistry. Cytoplasmic Granules / ultrastructure. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Periodic Acid-Schiff Reaction

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913428.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Lin WN, Huang HC, Wu CC, Liao CT, Chen IH, Kan CJ, Huang SF: Analysis of acinic cell carcinoma of the parotid gland - 15 years experience. Acta Otolaryngol; 2010 Dec;130(12):1406-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of acinic cell carcinoma of the parotid gland - 15 years experience.
  • CONCLUSION: In our experience, the prognosis for parotid gland acinic cell carcinoma (AciCC) is good.
  • Surgery alone would be sufficient in early-stage tumor.
  • OBJECTIVES: AciCC is a rare tumor in parotid gland malignancy.
  • The tumor stage distributions of the patients were 24%, 44%, 28%, and 4% for stages I, II, III, and IV, respectively.
  • [MeSH-major] Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Follow-Up Studies. Humans. Lymphatic Irradiation. Male. Middle Aged. Neoplasm Staging. Parotid Gland / pathology. Parotid Gland / surgery. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809887.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Dudeja V, Vickers SM, Saluja AK: The role of heat shock proteins in gastrointestinal diseases. Gut; 2009 Jul;58(7):1000-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By virtue of this protective function, HSPs have been shown to prevent acinar cell injury in acute pancreatitis.
  • Further, inhibition of HSPs has been shown to induce apoptotic cell death in cancer cells suggesting that inhibition of HSPs has a potential to emerge as novel anti-cancer therapy, either as monotherapy or in combination with other chemotherapeutic agents.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51490-9 [15371421.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1246-55 [15388581.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):1056-9 [15742415.001]
  • [Cites] World J Gastroenterol. 2005 Apr 14;11(14):2072-9 [15810071.001]
  • [Cites] Cell Stress Chaperones. 2005 Spring;10(1):46-58 [15832947.001]
  • [Cites] Biochem Pharmacol. 2005 Aug 15;70(4):580-9 [15993848.001]
  • [Cites] Exp Hematol. 2005 Aug;33(8):944-52 [16038788.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1049-58 [16038731.001]
  • [Cites] J Korean Med Sci. 2005 Oct;20(5):829-34 [16224158.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38729-39 [16172114.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 Feb;5(1):22-7 [16481277.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3193-9 [16707620.001]
  • [Cites] Curr Top Med Chem. 2006;6(11):1205-14 [16842157.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11318-22 [16844778.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2417-24 [17048249.001]
  • [Cites] Int Rev Immunol. 2006 Sep-Dec;25(5-6):353-75 [17169780.001]
  • [Cites] Cell Cycle. 2006 Nov;5(22):2592-601 [17106261.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):616-25 [17234771.001]
  • [Cites] Annu Rev Physiol. 2007;69:249-69 [17059357.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1123-32 [17363505.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):537-44 [16950797.001]
  • [Cites] J Nippon Med Sch. 2000 Jun;67(3):177-85 [10851351.001]
  • [Cites] Gastroenterology. 2000 Jul;119(1):220-9 [10889172.001]
  • [Cites] Nat Cell Biol. 2000 Aug;2(8):469-75 [10934466.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25665-71 [10806214.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6826-36 [10958679.001]
  • [Cites] J Clin Invest. 2000 Sep;106(6):773-81 [10995788.001]
  • [Cites] J Psychosom Res. 2000 Jun;48(6):569-77 [11033376.001]
  • [Cites] Ann N Y Acad Sci. 2000;926:122-5 [11193027.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):446-56 [11157751.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):18742-7 [11278554.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 24;286(3):433-42 [11511077.001]
  • [Cites] Cell Stress Chaperones. 2001 Jan;6(1):49-58 [11525243.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):839-43 [11533664.001]
  • [Cites] Gut. 2002 Jan;50(1):78-83 [11772971.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):425-35 [15314073.001]
  • [Cites] Cell Stress Chaperones. 2004 Summer;9(2):122-33 [15497499.001]
  • [Cites] Arch Pathol. 1968 Aug;86(2):117-26 [5660619.001]
  • [Cites] Am J Dig Dis. 1974 Jul;19(7):591-8 [4835329.001]
  • [Cites] Biol Chem Hoppe Seyler. 1988 May;369 Suppl:293-8